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The well-established “classical” model of haematopoiesis reflects a 
hierarchical decision-making process where early multipotent progenitors make an 
irrevocable decision to differentiate towards either the lymphoid or myeloid lineages 
through so-called Common Lymphoid and Common Myeloid progenitor 
intermediates respectively. However, the proposals for alternative differentiation 
pathways and the description of progenitor cells that contradict the lympho-myeloid 
dichotomy have prompted multiple revisions of the strict compartmentalized 
classical model. We have previously characterized a B220+ CD117int CD19- NK1.1- 
uncommitted and multipotent haematopoietic progenitor with combined lymphoid 
and myeloid potential that we called Early Progenitor with Lymphoid and Myeloid 
potential (EPLM). The emergence of high throughput methods enabling the 
investigation of single-cell whole-transcriptome profiles generates data that 
enhances the active debate regarding the heterogeneity of apparently 
phenotypically homogenous progenitors having different multiple lineage potentials. 
This thesis provides a detailed analysis of EPLM heterogeneity by combining the 
alternative and complementary “top-down” and “bottom-up” experimental designs.  
Using the “top-down” approach based on the expression of the cell-surface markers 
Ly6D, SiglecH and CD11c, we could subdivide EPLM into four subpopulations with 
distinct lineage biases. As revealed by the subsequent functional experiments, the 
Ly6D+ EPLM fraction was lymphoid restricted and contained most B-cell potential 
whereas the so-called triple negative (TN) EPLM expressing none of the above 
markers remained as a lympho-myeloid multipotent fraction and the potential 
precursor of the Ly6D+ subset. Subsequently, single-cell RNA sequencing (“bottom-
up” approach) of 152 Ly6D+ and 213 TN single cells revealed that in fact TN are 
composed of a mixture of cells where the myeloid potential is mainly due to the 
contribution of the G3 TN subset whereas the lymphoid potential resides in the G1 
TN clustered group of cells. This heterogeneity was masked in previous bulk 
molecular and functional experiments, thus demonstrating the power of single-cell 
RNA-sequencing technology to study heterogeneity in haematopoietic progenitors at 
an unprecedented resolution. Moreover, single-cell transcriptome profiles enabled 
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the detection in an unbiased manner of markers that better define cellular identity. 
Here we redefined the “top down” EPLM classification by identifying Terminal 
deoxynucleotide Transferase (TdT) as a potential marker with which to discriminate 
the lymphoid and myeloid potential of EPLM since, in addition to the previously 
identified lymphoid primed Ly6D+ cells, TdT is also expressed in the G1 TN fraction, 
which turned to be molecularly indistinguishable from the G2 Ly6D+ fraction. The use 
of other candidate markers such as Ebf1 and CD115 enabled us to prospectively 
isolate cells from different newly identified subgroups of EPLM and to confirm their 
genetic signatures with functional assays, thus supporting the increasing belief that 
the repertoire of genes expressed reflects the immediate lineage bias of that cell. 
Finally, within the Ly6D+ cells, we found a B-cell priming gradient and propose that 
the G1 Ly6D+ fraction is the direct precursor of the first B-cell committed stage, the 
CD117+ CD19+ Pro-B cell. Therefore, we favour the concept that haematopoiesis 
occurs through a process of graded commitment where molecular priming is 
initiated earlier than previously anticipated.  Overall, this study provides a valuable 
model demonstrating that previously characterized, phenotypically homogeneous, 
multipotent progenitor cells are in fact composed of mixtures of cells with differently 






3.1 Initiation of haematopoiesis 
 
Haematopoiesis is a well-orchestrated and tightly regulated process resulting 
in the formation of all blood cell types. In adult mammals, haematopoiesis starts in 
the bone marrow (BM) with a rare cell type called Haematopoietic Stem Cell (HSC) 
that has both self-renewal and multipotent capacities.  Self-renewal is the ability to 
generate cells that are identical to the mother HSCs without differentiation, thus 
allowing the maintenance of the stem cell pool size, while multipotency is the ability 
to differentiate into all functional blood cells.  
Self-renewal and differentiation of HSC requires a special environment, 
termed the hematopoietic stem cell niche, which provides the protection and the 
necessary signals for their maintenance and development [1, 2]. Two main 
microenvironments are suggested to form the bone marrow niches: the endosteal 
and the vascular niche [3]. The endosteal niche, located in the interface between 
bone and BM [4], includes osteoblasts, derived from mesenchymal precursors, that 
produce a number of cell-signalling molecules that contribute to the maintenance 
and regulation of HSC such as Jagged (ligand of Notch receptor), thrombopoietin and 
angiopoietin, SCF, chemokines or Wnt [5]. The vascular niche, located at the 
fenestrated endothelium of bone marrow sinusoids [4, 6], promotes proliferation 
and differentiation, active cycling and generation of short-term HSCs by producing 
factors important for mobilization, homing and engraftment of HSC such as vascular 
cell-adhesion molecule-1 (VCAM-1), stromal cell-derived factor-1 (SDF1) or fibroblast 
growth factor-4 (FGF4) [7]. An important function of the stem cell niche is to 
regulate the balance between cellular self-renewal and differentiation [2]. One 
mechanism that ensures this balance is the control of asymmetric/symmetric cell 
division. As a result of asymmetric division, one daughter cell maintains the mother 
stem cell fate and the other daughter cell becomes more committed to terminal 
differentiation [8, 9]. Several reported mechanisms argue for an intrinsic capability 
of HSCs to divide asymmetrically, exemplified by the unequal molecular segregation 
during cell division. Some examples are: the asymmetric distribution of regulatory 
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cell surface molecules (e.g. notch [10]) or cellular processes [11] in mammalian 
neurogenesis; asymmetric distribution of cellular organelles (e.g. p-granules in 
C.elegans [12]); asymmetric distribution of transcription factors and co-factors (e.g. 
Prospero/Miranda in Drosophila [13]); and asymmetric distribution of DNA (e.g. 
extrachromosomal rDNA circles, ERCs, in yeast [14]). Alternative to the intrinsic 
model, there is a post-mitotic model arguing that the observed differences in the cell 
fates of sister cells are due to post-mitotic mechanisms in which initially identically 
specified daughter cells influence each other’s cell fate (e.g. via Notch signalling 
pathway [15, 16]). Further investigations are required to resolve whether both 
models co-exist and to what extent each model contributes to different specification 
of daughter cells.  
Multi-potentiality of HSCs was first demonstrated by Osawa et al. after 
showing that a single mouse CD34low/- HSC reconstitutes haematopoiesis long-term 
in a lethally irradiated mouse [17, 18]. Similar results were reported by Notta et al. 
with single human HSCs engrafting NGS mouse [19]. Since most mature blood cell 
types are short lived, HSCs are ultimately responsible for the continuous and life-
long renewal of blood. Mature blood cells are produced at an impressive rate of 
more than one million cells per second in the adult human. 
The description of HSCs, and their isolation by fluorescence activated cell 
sorting (FACS), relies on the presence or absence of a range of cell-surface 
molecules. HSCs do not express markers that are associated with the various 
haematopoietic cell lineages (Lin-) including, for example, CD3 (T lymphocytes), B220 
and CD19 (B lymphocytes), CD11b (monocytes-macrophages), Ly-6G (neutrophils) 
and TER-119 (erythoid cells), and they express the two molecules c-Kit, a tyrosine 
kinase receptor for the cytokine stem cell factor (SCF), and Sca-1 a 
phosphatidynositol-anchored membrane protein of unknown function [20]. Thus, 
HSCs are enriched in the Lin-, Sca-1+, c-Kit+ fraction of bone marrow cells, termed LSK 
cells, that represent approximately 0.05% of nucleated adult mouse BM cells [21]. 
The LSK compartment contains cells that repopulate the entire haematopoietic 
system either long-term (LT-HSC) or short-term (ST-HSC). Three different FACS 
staining strategies describe the phenotype of the two LSK subsets. The original 
Weissman approach relies on Thy-1.1 and Flt3 (fms-like) tyrosine kinase, a type 3-
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receptor kinase, whose expression was observed to correlate with a loss of the 
capacity of HSCs to self-renew [22, 23]. In this model LT-HSCs are LSK Flt3- Thy1low 
and, ST-HSCs are LSK Flt3+ Thy1low. Later, in 2005, Jacobsen combined LSK markers 
with CD34 and Flt3 [22], a commonly used strategy. Thus Jacobsen et al. described 
LT-HSCs as LSK CD34- Flt3- and ST-HSC as LSK CD34+ Flt3-. Recently, Morrison made 
use of additional signalling lymphocyte activation molecule markers (CD150, CD48, 
CD229, and CD244) to subdivide LSK cells. Here, LT-HSCs are defined as LSK CD150+, 
CD48-/low, CD229-/low and CD244- while ST-HSC differ in CD229 expression and are 
defined as CD150+, CD48-/low, CD229+ and CD244- [23].  
HSCs differentiate into multipotent progenitor cells (MPPs), which gradually 
lose their multipotentiality while undergoing decision-making, expansion, and 
differentiation via intermediate lineage precursors giving rise to the final 
compartments of functional cells. The long-standing classical model of 
haematopoiesis [24], together with other versions [25], reflects a hierarchical 
decision-making process where early multipotent progenitors make an irrevocable 
decision to differentiate towards either the lymphoid or the myeloid lineage [26]. 
This clear lympho-myeloid separation is supported by the identification of 
progenitors of each lineage. Weissman and colleagues reported the so-called 
common lymphoid progenitor (CLP) [27] which can give rise to B and T lymphocytes 
and natural killer (NK) cells, and the common myeloid progenitor (CMP) [28] which 
can differentiate into the rest of the immune and blood cells. Thus, this traditional 
model illustrates single routes of differentiation to each end-cell type. However, over 
the past 15 years, the above strict compartmentalization of hematopoietic cells has 
been challenged. This is mainly due to the description of progenitor cells that 
contradict the lympho-myeloid dichotomy.  
 
3.2 Early Progenitor with Lymphoid and Myeloid developmental 
potential (EPLM) 
 
The first indication that haematopoietic development has much more 
plasticity than previously anticipated came from studies performed in mice deficient 
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for the transcription factor Pax5 [29]. The Pax5-/- mouse presents an absolute block 
in B-cell development at the Pro-B cell stage. Remarkably, and in contrast to wild-
type (WT) cells, Pax-5 deficient Pro-B cells had multilineage developmental potential 
since they could develop into myeloid, NK, and T cells both in vitro and in vivo [30-
32]. Moreover, even WT committed precursor B cells regain multipotentiality upon 
conditional inactivation of the Pax5 gene [32]. This demonstrates that progenitor 
cells that have progressed some way along a given lineage retain the ability to give 
rise to other cell types until a rather advanced stage of differentiation. However, 
whether such a degree of developmental plasticity occurs under physiological 
conditions is an unresolved issue. Subsequently, our laboratory detected in wild-type 
mouse BM a cell with similar properties to the Pax5-/- Pro-B cells. This cell has the 
capacity to differentiate into lymphoid and myeloid cells and was therefore called 
EPLM (Early Progenitor with Lymphoid and Myeloid developmental potential). EPLM 
cells were identified as B220+ cKitint CD19- and NK1.1- cells representing 0.2% of all 
nucleated BM cells [33] (Figure 1). In terms of phenotype, this progenitor is closely 
related to the CLP with the marked difference of B220 expression, EPLM being B220+ 
whereas CLP are B220-, and partially overlaps with the so-called Fraction A cells 
identified by Hardy and co-workers [34] (Table1 contains a comparison of the 
nomenclatures used for early B-cell developmental stages). Limiting dilution analysis 
of EPLMs cultured together with stromal cells and addition of appropriate cytokines, 
enabled the quantification of in vitro B, T and, myeloid precursor frequencies. EPLMs 
showed strong B-cell developmental potential and strong-to-moderate 
differentiation potential for T cells and myeloid cells (mostly macrophages). 










Therefore, this suggested that under physiological conditions the developmental fate 
of EPLM is mainly to become B cells. Reconstitution assays in order to assess the 
EPLM’s in vivo developmental potentials revealed their ability to transiently 
reconstitute both B and T cell compartments in sublethaly irradiated Rag2-deficient 
mice. 
Another cell that contradicts the classical lympho-myeloid lineage separation 
is the Lymphoid-Primed MultiPotent progenitor (LMPP), which has little potential for 
megakaryocyte or erythroid development while retaining other potentials [35]. 
Compared with EPLM, LMPP present slower kinetics in developing into lymphoid 
cells, hence suggesting an earlier and upstream location in haematopoietic 
development. Moreover, LMPP is the Flt3 positive high fraction of LSK and, in 
contrast with EPLM, is B220-. Together with the identification of new progenitor 
cells, the finding of alternative routes to end-cell types [36] prompted the necessity 
of proposing new models for the architecture of haematopoiesis.  
 
Table1. B-cell developmental stages in the bone marrow. Comparison of the nomenclatures used to identify 
developmental B cell subsets and how they relate to key VDJ recombination events (comprehensively reviewed 
in Osmond et al. [37], and Hardy et al. [38]). Table adapted from Hardy et al. [39]. 
 
3.3 Pair-wise model of haematopoiesis 
 
In collaboration with others, a few years ago our laboratory presented a new 
model of haematopoiesis called the pair-wise model [40, 41]. In contrast to the 
traditional hierarchical trees, this model outlines haematopoietic development in a 
cyclical representation. Fundamentally, the principle of an HSC giving rise to all blood 
cell types is the same. However, the intermediate progenitor stages are better 
illustrated. In the pair-wise model, the set of developmental potentials that have 
Osmond Melchers	and	Rolink Hardy Status	of	Ig	loci
Pro-B Pre-pro	B	/	EPLM A Germline
Pro-B B D-JH	rearrangement
C VH-DJH	rearrangement
Pre-B Large	pre	B C' VHDJH	pairs	with	λ5-Vpre-B
Pre-BCR	surface	expression
Small	pre	B D Vκ-Jκ	or	Vλ-Jλ	rearrangement	
Immature	B Immature	B E Complete	BCR	(receptor	editing	can	occur)
Developmental	stages
 12 
been shown experimentally are represented as a continuum by arcs (Figure 2). As 
development proceeds, the arcs become shorter indicating that developmental 
potentials are gradually restricted and ultimately cells become committed to a 
differentiated cell fate (as shown by the outermost arc). As its name indicates, this 
model depicts a series of pair-wise developmental relationships between the various 
haematopoietic lineages. This infers that only certain bi-potentialities are permissive. 
For example, a bi-potent T lymphocyte-megakaryocyte cell should not exist, and has 
not been described to date. 
 
 
The pair-wise model has no lineage branching patterns and therefore, does 
not assume a single preferred route to a particular end-cell type. In other words, 
HSCs can reach a specific differentiated blood cell through more than one type of 
intermediate progenitor. For instance, dendritic cells (DC) can be derived from either 
CLP/EPLM or CMP, indicating that DC can have both lymphoid and myeloid origin 
[36]. Moreover, multiple routes have been demonstrated towards neutrophils and 
monocytes [42, 43]. Another advantage is that the pair-wise model maintains the 
possibility that progenitors can move in the opposite direction and regain 
multipotentiality -as is the case for the Pax5-/- Pro-B cells. Overall, the above-
described model, which includes the recently identified progenitors and allows 
Figure 2. Pair-wise model of haematopoiesis. Illustrated is a fate choice continuum with an invariant series of pair-
wise developmental relationships between haematopoietic cells’ fates. 
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alternative routes, leads to a viewpoint that haematopoiesis is a more versatile and 
less strictly compartmentalized process than previously thought.  
In line with the description of progenitor cells that have multiple lineage 
options, there is an increasing debate regarding their heterogeneity. It is highly likely 
that multipotent progenitor cells presently viewed as a homogeneous population 
will be divided into subsets with lineage biases or even into already committed 
subsets. In turn, some end-cell types will be probably further divided into numerous 
subtypes. To what extent progenitor cell populations, and their mature progeny, are 
heterogeneous is very much dependent on the quantity of new and existing cell-
surface markers that can be used to define new subpopulations. In this regard, 
together with the improvement of traditional flow cytometer-based technologies, 
allowing the simultaneous detection of an increasing number of markers, the 
explosion of high throughput technologies, such as RNA sequencing that enable the 
parallel screening of a large amount of markers in an unbiased manner, has been of 
a pivotal importance. 
 
3.4 Single-cell RNA sequencing: the method that dissects heterogeneity 
 
In the last couple of years, RNA sequencing at the single-cell level has 
emerged as an important technology for interrogating the degree of heterogeneity 
in a population. This technology, which can be performed at a whole-transcriptome 
scale with unprecedented resolution, consists of extracting the RNA from individual 
cells followed by a sequencing process similar to that for bulk RNA sequencing. 
When RNA sequencing is performed at the population level, as has been the case for 
most studies, we obtain an average transcription profile of thousands or millions 
pooled cells. This, masks the true distribution of gene expression levels across 
individual cells, thus hampering the elucidation of whether a subset of cells is 
responsible for the expression of a given gene or even if it is the major contributor of 
a function in a seemingly homogeneous population [44]. Therefore, it is crucial to go 
to the single-cell level where there is no averaging effect.  
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3.4.1 Technological advances 
 
The first mRNA sequencing whole-transcriptome analysis of a single cell was 
reported in 2009 by Tang and co-workers. Using a novel mRNA sequencing assay 
they detected expression of 5,270 genes in a single mouse blastomere [45], thus 
greatly overcoming the limited throughput of a couple of hundred genes that can be 
analysed by single-cell qRT-PCR. Moreover, in contrast to qPCR, mRNA sequencing 
based technology provides a comprehensive view of the transcriptome profile in one 
cell in an unbiased manner or, in other words, without requiring prior knowledge 
and selection of genes of interest. However, the method reported relies heavily on 
manual manipulation   of   cells   and   reagents and can only process few cells per 
hour. The limitation of manual handling, either during the capturing or during the 
later processing steps, also occurs in other single-cell RNA sequencing technologies 
such as laser-capture microdissection or single-cell sorting into a multi-well plate. 
Therefore, researchers rapidly attempted the development of automated methods.  
Automation of the single-cell RNA sequencing process became a reality with 
the emergence of chip-based microfluidics devices. In 2013, Fluidigm launched the 
“C1™ Single-Cell Auto Prep System” helping expand access to the single-cell RNA 
sequencing technology [46, 47]. The C1 system provides a completely automated 
workflow that integrates both the capture of single cells in a microfluidic chip and 
the later processing steps including washing, lysis, reverse transcription and, PCR 
pre-amplification. In addition, the major strength of microfluidics is the manipulation 
of minute volumes, working in a nanoliter reaction scale. As a result, albeit allowing 
the processing of only a few tens of cells per experiment, this system presents higher 
reproducibility, more cost-effective reactions and increased sensitivity compared 
with classical methods [48]. In parallel with its commercialization, the journal 
“Nature Methods” declared single-cell sequencing as the method of the year 2013. 
As a consequence, the past few years have seen a burst of papers from laboratories 
around the world that have developed expertise in single-cell approaches. These 
papers include new single-cell technologies and provide evidence for its valuable 
application in many areas. 
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Regarding the development of new technologies, the state-of-the-art has 
shifted towards scaling up the number of cells that can be analysed in parallel and in 
an affordable manner in terms of time and costs. Recently, Klein et al. and Macosko 
et al. have developed two advanced droplet-based microfluidics methods termed 
Drop-seq [49] and inDrop sequencing [50] respectively. Both methods, published in 
the same issue of the journal Cell, massively increase the throughput to several 
thousand of cells while reducing the cost of sequencing. Moreover, despite there 
being some differences between the experimental protocols, both publications rely 
on the same fundamental principle. The cells are separated into nanoliter-sized 
aqueous droplets in carrier oil as reaction chamber. Each reaction chamber contains 
microparticles coated with unique cell barcodes and Unique Molecular Identifiers 
(UMIs). Although droplet microfluidics is not a new technology, this efficient 
barcoding strategy makes it an attractive method and, altogether, has big potential 
for commercialization.  
To date, apart from droplet-based microfluidics, a variety of other 
microfluidics techniques for single-cell trapping exist. Some examples are 
hydrodynamic trap [51], magnetic trap [52, 53], acoustic trap [54], dielectrophoretic 
trap [55], and optical trap [56]. All this together exemplifies increasing interest for 
single-cell handling technologies and creates anticipation for exciting biological 




Single-cell transcriptomics offers a wide range of applications that have 
already enabled some advances in a broad variety of fields apart from immunology. 
Examples include: oncology, with the dissection of tumour cell heterogeneity [57], 
the identification of subgroups associated with anti-cancer drug resistance [58], and 
the analyses of rare circulating tumour cells [59] or cancer stem cells; embryology, 
with new insights into the gene regulatory networks controlling early stages of 
embryonic development [45, 60-62]; neurobiology, with the unravelling of the 
complex cellular composition of the mouse hippocampus while uncovering novel 
markers and cell types [47]; or microbiology, with the opportunity of sequencing 
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uncultivated microbial eukaryotes at the single-cell level and identifying new species, 
unknown microbial functions and revised evolutionary relationships between 
eukaryotes, bacteria and archea [63, 64]. 
In immunology, single-cell molecular profiling is providing valuable 
information on the differentiation and function of the immune cells both at the 
steady state and during immune responses. Moreover, it is opening up a new avenue 
for finding markers that better describe cell phenotypes in an unbiased manner. 
During the forthcoming years, it is predicted that the identity of many immune cells 
will be redefined while possibly new cell types and subtypes will emerge. Indeed, 
several studies have already pointed in this direction. Mahata et al. identified a Th2 
subpopulation contributing to the maintenance of T-cell homeostasis. It is of interest 
that the Th2 subset, characterized by the expression of a specific enzyme (Cyp11a1), 
could be isolated by using surface molecules whose expression correlates with 
enzyme expression, thus allowing for the first time a broad ex vivo functional 
validation of a new cell type discovered by single-cell RNA sequencing [65]. Similarly, 
Shalek et al. found a very small subset of cells among mouse bone-marrow-derived 
dendritic cells. Those cells, termed precocious, are the first ones that produce and 
secrete a wave of interferon during antiviral responses [66].  Another example with 
novel subsets is a recently published paper providing a detailed study about the 
inter-cellular transcriptomic variation within the traditionally classified classical, 
intermediate and non-classical monocytes [67]. In the publication, Gren et al. reveal 
that each group of monocytes contains further subgroups with distinct genetic 
signatures according to their activation status and differentiation. This indicates the 
ability of single-cell transcriptomics to discover cell heterogeneity within defined cell 
populations. 
However, as a proof of concept, massive parallel single-cell RNA sequencing 
has also been applied to more complex and heterogeneous systems such as the 
spleen [68] or peripheral blood mononuclear cells (PBMCs) [53]. Apart from the 
identification of previously unknown hidden subpopulations, this approach could 
reconstitute the global cell heterogeneity within splenic tissue and PBMCs, thus 
envisaging the opportunity to redefine our knowledge on lineage hierarchy. In fact, a 
number of studies have amplified the current hematopoietic classifications and 
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differentiation trajectories through the detection of transient or intermediate cell 
states [69-71]. For instance, Paul et al. identified seven subgroups of c-Kit+ Sca1- Lin- 
sorted cells representing a gradient of erythrocyte transcription, from expression of 
early progenitor genes towards the up-regulation of functional genes [69]. It is of 
note that, unlike current models, none of the seven subsets co-expressed 
megakaryocyte genes. Therefore, they suggested that the standard gating and 
sorting for megakaryocyte-erythrocyte progenitors (MEP) might be termed 
erythrocyte progenitors (EP) instead. This exemplifies the necessity of revising the 
identity of the different immune cells as well as their subtypes, lineages and 
composition within tissues. 
In conclusion, the studies reported to date have convincingly demonstrated 
that single-cell RNA sequencing is a powerful approach that can be used in many 
applications such as exploring cellular heterogeneity in a population, studying 
differentiation dynamics, redefining cell identity, or identifying rare cell types among 
others.  Excitingly, it is expected that application of this technology will continue to 
expand as the techniques and analysis tools evolve.  
 
3.5 The role of IL-7 and Flt3L cytokines in lymphocyte development 
 
Cytokines are the pivotal external factors that deliver environmental signals 
to control haematopoietic cell development. Their mode of action can be viewed as 
either instructive or permissive [72]. In the instructive model, cytokines act directly 
on progenitor cells to drive them towards a specific lineage by actively inducing the 
initiation of a lineage-specific gene program. In contrast, in the permissive model 
commitment occurs in a cell-autonomous and stochastic manner and cytokines act 
to selectively allow cells committed to a particular lineage to survive and/or 
proliferate [73, 74]. The precise instructive versus permissive role of cytokines in 
haematopoiesis remains controversial [75-77]. Two important cytokines for T- and 
B–lymphocyte development are IL-7 and Flt3L since their receptors are co-expressed 
in a narrow window immediately before commitment and mutant mice show 
impaired lymphoid development [78-81].  
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IL-7 was originally identified as a growth factor for B-cell progenitors [82]. 
Later on, IL-7 activity on thymocytes and T-cell survival was also reported [83]. 
Subsequently, a specific receptor for IL-7, expressed in both B- and T-cell 
progenitors, was identified [84]. Mice lacking either the cytokine [81] or its receptor 
(IL-7Rα) [80] have a leaky arrest of T-cell development at the DN2 stage [80, 81] and 
absence of γδT cells [85], whereas a dramatic defect in B-cell generation with a block 
at the Pro-B cells stage occurs. Reports with over-expression of the pro-survival gene 
Bcl2 demonstrated that whereas the T-cell defect is rescued, thus suggesting a 
permissive role of IL-7 in early T-cell development [86, 87], B-cell development is not 
re-established [88, 89], arguing for an instructive role of this cytokine in B-cell 
commitment at least in mice. Interestingly, humans with defects in IL-7 signalling 
display a normal B-cell development [90, 91]. However, an in vitro system has 
provided clear evidence that IL-7R signalling through Stat5 alone is not sufficient to 
induce transcription of Ebf1 and Pax5 [92], indispensable for B-cell commitment, 
therefore arguing for an important but redundant action of IL-7 during commitment 
to the B-cell lineage [93, 94]. Therefore, while the importance of IL-7 as a survival 
and growth factor for committed B-cell progenitors is well established, its instructive 
role through Ebf1 and Pax5 up-regulation remains unclear.  
Flt3 ligand (Flt3L) is one of the essential cytokines for cell survival and 
proliferation during early haematopoiesis [95, 96]. Its function has gained much 
attention since mutations in Flt3L signalling are commonly found in Acute Myeloid 
Leukaemia (AML) [97]. Using flow cytometry, its receptor (Flt3) has been detected as 
early as the non-self-renewing MPP stage of development [98]. Thereafter, several 
downstream myeloid and lymphoid progenitors continue to express Flt3 with the 
exception of megakaryocyte-erythrocyte progenitors [99]. Flt3 expression is 
extinguished upon lineage commitment and, among differentiated cells, only 
dendritic cells retain Flt3 on their surface. For instance, during B-cell commitment 
Pax5 expression directly antagonizes that of Flt3 [100]. In the thymus, Flt3 
expression is used to identify the earliest and uncommitted thymocyte 
subpopulation with remaining B-cell developmental potential [101-103].  Mice with 
targeted gene disruption of Flt3 [78] or its ligand [79] do not exhibit a complete loss 
of any haematopoietic population but reduced numbers of B, DC and NK cells [78, 
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79]. Moreover, upon transplantation, BM progenitors from Flt3-/- or Flt3L-/- mice 
reconstitute the B-cell compartment poorly [78, 79] and Flt3L was found to be 
essential for maintaining normal numbers of uncommitted B-cell progenitors [104]. 
Therefore, these results suggest a survival and proliferative action of Flt3L during B-
cell development, rather than instructive. It is probable that Flt3L signalling exerts its 
function in concert with signalling from other cytokines such as SCF or IL-7 [92, 105]. 
This is manifested in cultures of lymphoid progenitor cells, such as ETP, CLP or EPLM, 
in the presence of IL-7, where Flt3L provides and additive anti-apoptotic effect while 
stimulating proliferation [106, 107]. 
 
3.6 Flt3Ltg mouse 
 
Until recently, both bulk and single-cell RNA sequencing required a 
considerable amount of starting material. For bulk experiments, it was about 500 
nanograms of RNA per sample, while for the single-cell capturing step using the C1 
platform the starting density recommended in the “single-cell preparation guide” 
from fluidigm is 166-255 cells/µL and 5-20 μL are loaded into the chip. To overcome 
this limitation, because the EPLM is a rare population, we made use of a mouse 
model, the Flt3 ligand transgenic (Flt3Ltg) mouse, to isolate EPLM and other 
progenitor populations in greater numbers.  
Initially, Ceredig et al. showed that apart from DC, increased in vivo Flt3L 
availability after several injections led to transient expansion of Flt3+ progenitors 
with either myeloid or lymphoid developmental potential or both [108]. Later on, 
our laboratory generated a transgenic mouse with sustained over-expression of 
human Flt3L, thus providing for the first time a detailed in vivo analysis of the effect 
of this cytokine on different haematopoietic lineages [109]. Examination of Flt3Ltg 
mice confirmed the importance of Flt3L in DC development. Moreover, the 
transgenic mice presented a tremendous expansion of almost all haematopoietic 
progenitors in the BM with the exception of MEP. The decrease in MEP occurred in a 
rapid fashion when WT mice were injected with recombinant Flt3L, therefore 
suggesting for the first time an instructive role for the Flt3L cytokine. Tsapogas and 
co-workers proposed that an increased level of Flt3L guides haematopoietic 
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development towards the lymphoid-myeloid fate at the expense of the 
megakaryocyte-erythrocyte fate [41, 109]. This provides an explanation for the 
decreased platelet counts and the consequent development of anaemia in Flt3Ltg 
mice.  
The EPLM compartment is a good 
example of the tremendous expansion of 
progenitors in the BM of Flt3Ltg mice. In 
fact, the number of EPLM cells was 
increased by 14-fold when compared to WT 
mice (Figure 3). Therefore, the Flt3Ltg 
mouse is an excellent tool for the isolation 
of large numbers of EPLM and other 
progenitor cells for further in vitro and in 
vivo experiments, transcriptome profiling or 




Figure 3. Total numbers of CMP, CLP and EPLM in 
the BM of WT (white symbols) and Flt3Ltg (black 
symbols) mice (5-7 mice per group). ***P<0.0001. 
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4. Aim of the project 
 
In this thesis we sought to characterize a previously identified uncommitted and 
multipotent progenitor cell called EPLM with the aim to: 
 Dissect EPLM heterogeneity by combining the use of cell surface markers, 
such as Ly6D, SiglecH and CD11c, the so-called “top down” experimental 
strategy, with single-cell RNA sequencing, “bottom up” approach. 
 Unravel whether EPLM phenotypic or molecular heterogeneity causes 
different sets of potentials in the identified subpopulations by in vitro limiting 
dilution assays and in vivo reconstitution experiments. 
 Study the precursor-product relationship among the subpopulations in bulk 
culture with cytokines. 
 Identify markers that better define cellular identity of the EPLM 
subpopulations in an unbiased manner, by single-cell RNA sequencing. 
 Utilize the identification of EPLM subpopulations in order to study the role of 
cytokines (Flt3L and IL-7) in B-cell commitment (von Muenchow et al. 









C57BL/6 (B6), B6 Rag2-deficient [110], B6 FLT3L transgenic (Flt3Ltg, [109]) 
and Ebf1ihCd2/+-Flt3Ltg mice used herein were 6 to 11 weeks old and matched by age 
and sex for each experiment. All mice were bred and maintained in our animal 
facility under specific pathogen-free conditions. All animal experiments were carried 
out according to institutional guidelines (authorization numbers 1886 and 1888 from 
Kantonales Veterinäramt, Basel). 
Ebf1ihCd2/+ mice were provided by Prof. Meinrad Busslinger and co-workers 
[111]. These mice had been generated by inserting an internal ribosome entry 
sequence (IRES)-hCd2 (ihCd2) reporter gene into the 3’ untranslated region of the 
Ebf1 gene. We next crossed the Ebf1ihCd2/+ reporter to the Flt3Ltg mice, thereby 
generating the Ebf1ihCd2/+-Flt3Ltg mice. 
 
5.2 Flow cytometry and cell sorting 
 
Bone marrow cell suspensions were obtained from femurs of the two hind 
legs of mice. Bones were flushed with a 2ml syringe filled with PBS containing 0.5% 
BSA and 5mM EDTA. Afterwards, single-cell suspensions were subjected to ACK 
treatment for erythrocyte depletion, stained with the appropriate combination of 
antibodies for 30 minutes at 4°C, and washed for subsequent flow cytometry or cell 
sorting. The following antibodies were used (from BD Pharmingen, 18 eBioscience, 
BioLegend, or produced in house) with names in brackets describing the 
corresponding clone: anti-B220 (RA3-6B2), anti-CD117 (c2B8), anti-CD19 (1D3), anti-
NK1.1 (PK136), anti-SiglecH (551), anti-CD11c (HL3), anti-Ly6D (49-H4), anti-CD115 
(AFS98), anti-hCD2 (RPA-2.10) conjugated with FITC, PE, PE/Cy7, APC, Bv421 or 
Biotin plus streptavidin-Bv650. For detection of TdT, cells were fixed and 
permeabilized after cell-surface staining using the Foxp3 Fix/Perm buffer kit 
(eBioscience), and subsequently stained with APC-conjugated anti-TdT (19-3) 
according to the supplier’s protocol. Flow cytometry was performed using a BD LSR 
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Fortessa (BD Biosciences) and data were analyzed using FlowJo v9.8 Software 
(Treestar). For cell sorting, a FACS Aria IIu (BD Biosciences) was used (>98% purity). 
 
5.3 In vitro limiting dilution assay 
 
ST2 [112], OP9 [113] and OP9 stromal cells expressing the Notch ligand Delta-
like 1 (OP9-DL1) [114] were plated in a 96-well flat-bottom plate one day prior to co-
culture at 3x103 cells per well. The following day, semi-confluent stromal cells were 
γ-irradiated with 3000 rad using a Cobalt source (Gammacell 40, Atomic Energy of 
Canada, Ltd) at 100 rad/min and co-cultured with graded numbers of sorted 
haematopoietic progenitors in 48 replicates (or as indicated). Cells were maintained 
as a monolayer in IMDM supplemented with 5x10-5M β-mercaptoethanol, 1mM 
glutamine, 0.03% w/v Primatone (Quest Naarden, The Netherlands), 100U/mL 
Penicillin, 100 μg/mL Streptomycin and 5% FBS (Amimed) at 37°C in a humidified 
atmosphere containing 10% CO2 in the air. OP9 and OP9-DL1 co-cultures were 
additionally supplemented with 10% IL7-conditioned medium. After 10 days (for OP9 
cell cultures) or 15 days (for OP9-DL1 and ST2 cell cultures), wells were inspected 
using an inverted microscope. Wells containing colonies of more than 50 cells were 
scored as positive. For each experiment, the frequency of negative wells was plotted 
against the number of haematopoietic progenitors plated and the fraction of 
progenitor cells developing B-cell, T-cell or myeloid colonies was estimated 
considering plating efficiency that follows a Poisson distribution. 
 
5.4 In vivo reconstitution assay 
 
Recipient Rag2-deficient mice were -irradiated using a Cobalt source as 
previously described at a dose of 400 rad 4h prior to reconstitution. Indicated 
numbers of sorted haematopoietic progenitors from donor mice (B6, Flt3Ltg or 
Ebf1ihCd2/+-Flt3Ltg as specified) were injected intravenously. After 3 weeks, spleen 




5.5 Bulk cultures with cytokines 
 
A number of 5x104 sorted haematopoietic progenitors from Flt3Ltg mice 
were cultured with 50ng/ml Flt3L prepared in-house and 10% IL-7 conditioned 
medium in a 24-well flat-bottom plate. Cells were maintained as previously indicated 
and from day 2 to day 6, one well containing cells from each population was 
analysed by flow cytometry for Ly6D and CD19 expression. 
 
5.6 Statistical analysis 
 
Statistical analysis was performed with GraphPad Prism v6.0f software. Two-
tailed unpaired Student t tests were used for statistical comparisons. Data are 
presented as mean values ± SEM (n.s. not significant or P > 0.05, *P ≤ 0.05, **P ≤ 
0.01, ***P ≤ 0.001, ****P ≤ 0.0001). 
 
5.7 Bulk RNA sequencing 
5.7.1 Sample acquisition 
 
Ly6D+ and TN EPLM subpopulations as well as CD115- TN and Pro-B cells were 
sorted from femurs of 2-pooled male Flt3Ltg mice (6 to 8 weeks of age). After each 
sort, cells were centrifuged, resuspended in 0.5ml of TRIzol reagent and stored at      
-80°C for later total RNA extraction. From the Ly6D+ and TN samples, 100μl 
containing ~3 x104 cells were previously used for the capture of single cells. 
 
5.7.2 RNA extraction 
 
Total RNA was extracted from ex-vivo sorted samples using TRIzol-based 
method [115, 116]. Briefly, 1x105 to 3x105 cells were lysed in 0.5ml of TRIzol reagent 
and 0.1ml of chloroform was added per 0.5ml TRI reagent. After incubation and 
centrifugation for phase separation, the aqueous phase containing the RNA was 
recovered and mixed with isopropanol in a 1:1 ratio for RNA precipitation. Following 
15min incubation and centrifugation, the supernatant was discarded while the RNA 
pellet was first washed with 75% ethanol and subsequently resuspended with 20μl 
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of DEPC treated water. Concentration and 260/280 purity ratio was initially 
determined using NanoDrop 1000 Spectrophotometer (Witec AG). Selected RNA 
samples were stored at -80°C for later usage. 
 
5.7.3 RNA quality 
 
Either 500ng or 1μg of total RNA per sample was sent to the Genomics Facility at the 
D-BSSE (Basel) for quality control, library preparation and sequencing. Quality and 
level of degradation of the extracted RNA was assessed with RNA integrity number 
(RIN) assigned by the Agilent 2100 Bioanalyzer instrument using either the Nano or 
the Pico Agilent RNA 6000 kit (Agilent Technologies). Samples with a RIN value over 8 
and presenting clean peaks were considered for further analysis. The RNA quantity 
was measured by the Infinite M1000 PRO - Tecan instrument using the Quant-iT 
RiboGreen RNA Assay Kit.  
 
Figure M1. Quantification of raw sequenced data for the Ly6D
+
, TN and Pro-B samples. (A) Number of 
sequenced reads per sample. (B) Percentage of reads that mapped to the mouse genome (mm9). (C) Number of 
counts per sample (library size) considering reads mapped to genes (exons only). (D) The total number of 
detected genes per sample (with at least 1 count). 
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5.7.4 Library preparation 
 
For the preparation of sequencing libraries, the TruSeq Stranded mRNA LT 
Sample Preparation kit was used following the manufacturer’s guide [117]. The 
polyA containing mRNA molecules were purified using poly-T oligo attached 
magnetic beads and subsequently fragmented using divalent cations under elevated 
temperatures. Afterwards, the RNA fragments were copied into first strand cDNA 
using reverse transcriptase and random primers. Strand-specificity information was 
achieved by replacing dTTP with dUTP during the second strand cDNA synthesis. To 
prevent self-ligation of the double-stranded cDNA, the 3’ ends of the blunt 
fragments were adenylated followed by ligation of barcoded adapters suitable for 
Illumina-based sequencing. The product was subjected to 15 cycles of PCR 
amplification.  
Size and purity of the library fragments was assessed by the Fragment 
Analyzer using the NGS Fragment 1-6000bp method (average fragment size 321bp, 





Indexed DNA libraries were pooled in equal volumes and loaded on one 
NextSeq 500 High Output flow cell (Illumina). Single-end sequencing was performed 
on the Illumina NextSeq™ 500 Sequencing System (D-BSSE, Basel) for 81 cycles 
yielding in 21 to 35 millions of reads, 81-mers, per sample (Fig. M1 A). 
The Genomics Facility with the Illumina pipeline performed de-multiplexing 
and reads were transferred in the FastQ format via openBIS. A quality control of the 
sequenced data was performed using the FastQC tool 
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc/, Version 0.11.3). All 
samples comprised high number of reads (> 21 millions) with median Quality Score 
(QS) of 35, a GC content distribution equivalent to the expected theoretical 
distribution (~52%), a sequence duplication level typical for RNA-seq samples, and 





Figure M2. Example of quality control of raw sequence data (FASTQC). (A) Quality scores for individual positions 
within read sequence (over all reads). (B) Quality score distribution over all sequences. (C) GC content 
distribution over all sequences. Red: theoretical GC content (%); blue: observed GC content (%). (D) Distribution 
of sequence length over all sequences. (E) Relative number of sequences with different degrees of duplication. 
(F) Frequency of contamination by sequencing adapters. Replicate 2 of Ly6D group is taken as a representative 
example.  
 
5.7.6 Pre-processing of sequencing data 
 
All downstream analysis was performed using the open source software R 
accessed via RStudio server (R version 3.2.0). Sequencing reads were aligned to the 
mouse genome assembly, version mm9 (downloaded from UCSC 
http://genome.ucsc.edu), with SpliceMap [118, 119], included in the R/Bioconductor 
package QuasR, version 1.10.1. Splice-map was also capable of mapping reads that 
cover exon junctions. More than 80% of total reads were successfully mapped for 
each sample (Fig. M1 B). Subsequently, a count table with gene expression levels 
was generated using the qCount function from QuasR package and coordinates of 
RefSeq mRNA genes (http://genome.ucsc.edu, downloaded in December 2013). The 
expression level was defined as a number of reads that started within any annotated 
exon of a gene (exon-union model). Total counts per sample ranged from 13 to 22 
millions (Fig. M1 C), the so-called library size. Genes with no counts across all 
samples were filtered out from the analysis. For 17,290 genes at least 1 read was 
detected across all samples, corresponding to ~14,800 genes per sample (Fig. M1 D).  
Raw counts were normalized between samples with the TMM method 
(weighted trimmed mean of M-values [120]), expressed as counts per million 
mapped reads (CPM), and transformed to the log2-scale (log2CPM). 
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5.7.7 Data analysis 
 
Differential expression analysis was performed using edgeR v3.12.1 [121]. A 
prior count of 8 was used in order to minimize the large log-fold changes for genes 
with small number of counts. Genes with a false discovery rate (FDR) <0.05 and 
abs|log2(FoldChange)| >1 were considered differentially expressed genes (DEG). For 
principal component analysis (PCA) average gene expression was centred to zero and 
only the top 50% of genes with highest variance across analysed dataset (calculated 
as inter-quartile range) were used. PCA plots were generated with the ggplot2 v2.1.0 
R package. Heatmap with sample pair-wise Pearson’s correlation coefficients were 
also generated with the same subset of genes and visualized with the NMF v0.20.6 R 
package. Annotated heatmap of gene expression variation of the indicated genes 
across the samples was also generated with the NMF v0.20.6 R package. Average 
gene expression was centred to 0 and distances were calculated from Pearson’s 
correlation values of samples using the Euclidean method. MA and Volcano plots 
were produced using custom R scripts. Gene ontology enrichment analysis was 
performed with the DAVID v6.7 bioinformatics database, based on Fisher’s Exact 
method [122, 123]. Gene ontology terms of DEG were determined to be significantly 
enriched when Pval <0.05. 
 
5.8 Single-cell RNA sequencing 
 
5.8.1 Capture of single cells 
 
Single cells were captured from ex-vivo sorted haematopoietic progenitors on 
a small-sized (5-10μm cell diameter) C1 Single-Cell Auto Prep IFC for mRNA 
sequencing (Fluidigm) using the Fluidigm C1 system. Cell diameter of the Ly6D+ and 
TN cells, imaged on Leica DMI 4000 microscope and measured with ImageJ software, 
was similar and homogeneous, 8.54 and 8.77μm respectively (Fig. M3 A). Therefore, 
no bias due to cell size or morphology was expected during the capturing. Cells were 
loaded onto the chip at a concentration of ~300 cells/μl as recommended by the 
manufacturers and the 96 chambers were inspected by phase-contrast microscopy 
to determine the number of captured single cells. A total of 3 chips per population 
were used yielding a good overall capture efficiency, 178 Ly6D+ and 232 TN single 
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cells (Fig. M3 B,C). Subsequently, cells were lysed, the polyA containing mRNA 
molecules were hybridized to oligo-dT and whole-transcriptome full-length amplified 
cDNA was prepared by template switching on the C1 fluidigm chip according to the 
manufacturer’s protocol, using the SMARTer Ultra Low RNA kit for the Fluidigm C1 
System (Clontech). Quantification of cDNA was done with Quant-iT PicoGreen® 
dsDNA Assay Kit; TEcan instrument. 
Figure M3. Single-cell capturing. (A) Average diameter of Ly6D
+
 cells (n=24) and TN cells (n=36) determined by 
phase-contrast microscope and measured with ImageJ. (B) Representation of a single-cell captured in one of the 
96 chambers of the C1 Fluidigm small chip. Picture taken with phase-contrast microscope in the second chip run 
of TN cells. (C) Capture efficiency. Number (n°) and percentage (%) of single-cells captured per chip (run) or per 
population (total).  
 
5.8.2 Library preparation 
 
Illumina single-cell libraries were constructed in 96-well plates using the 
Nextera XT DNA Library Preparation Kit (Illumina) following the protocol supplied by 
Fluidigm (“Using C1 to Generate Single-Cell cDNA Libraries for mRNA Sequencing”). 
Briefly, 0.1-0.3ng of harvested cDNA was subjected to tagmentation, a process in 
which the DNA fragmentation and sequencing adapter ligation occurs in a single step 





Indexed DNA libraries originated from single cells captured in 3 different 
chips (288 libraries) were pooled in equal volumes and loaded on one NextSeq 500 
High Output flow cell (Illumina). Single-end sequencing was performed on the 
Illumina NextSeq™ 500 Sequencing System (D-BSSE, Basel) for 76 cycles. 
As for the bulk RNA sequencing, reads (76-mers) were received after de-
multiplexing in the FastQ format and checked for quality using the FastQC tool 
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc/, Version 0.11.3). Only 
the FastQ files corresponding to C1 chambers with a single cell were selected for 
downstream analysis, thus excluding the ones derived from doublets, debris or 
empty chambers (previously determined by phase-contrast microscopy). We 
obtained a total of 360 million reads for the Ly6D+ and 371 million reads for the TN. 
The average number of reads per cell was 2x106 for the Ly6D+ and 1.6x106 for the TN 
(Fig. M4 A). 
 
Figure M4. Quantification and quality control of raw sequenced data for Ly6D
+
 (left panels) and TN (right 
panels) single cells. Per cell distribution of (A) number of sequenced reads, (B) percentage of reads mapped to 
the mouse genome (mm9) out of the total number of reads, (C) counts (library size) considering reads mapped to 
genes (exons only) and, (D) total number of genes detected (with at least 1 count). Ly6D
+
 n=178; TN n=213. Blue 
line: mean; dotted red line: thresholds applied to the data (any cells not meeting these thresholds failed the 
quality control and were excluded from the analysis). 
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5.8.4 Pre-processing of sequencing data 
 
All downstream analysis was performed using the open source R software 
accessed via RStudio server (R version 3.2.0). Sequencing reads were aligned to the 
mouse genome assembly, version mm9 (downloaded from UCSC 
http://genome.ucsc.edu), with SpliceMap [118, 119], included in the R/Bioconductor 
package QuasR, version 1.10.1. Approximately 80% of total reads were successfully 
mapped for each sample (Fig. M4 B). Subsequently, a count table with gene 
expression levels was generated using the qCount function from QuasR package and 
coordinates of RefSeq mRNA genes (http://genome.ucsc.edu, downloaded in 
December 2013). The expression level was defined as the number of reads that 
started within any annotated exon of a gene (exon-union model). Total counts per 
cell were approximately 810,000 for the Ly6D+ and 720,000 for the TN (Fig. M4 C), 
the so-called library size. Genes with no counts across all samples were filtered out 
from the analysis. At least one read per gene was detected for a total of 14,814 
genes across all cells, corresponding to approximately 3,500 expressed genes per cell 
in both Ly6D+ and TN (Fig. M4 D).  
During the quality control, cells having less than 60% of mapped reads, less 
than 200,000 counts, or less than 800 detected genes were filtered out from further 
analysis (dotted red lines in Fig. M4). In total, 365 (152 Ly6D+ and 213 TN) cells out of 
410 or 89% passed these criteria. 
Raw counts were normalized between cells and genes, expressed as 
fragments per kilobase of transcript per million mapped reads (FPKM). For 
visualization purposes, 1 was added to FPKM values and transformed to the log2-
scale (log2FPKM). 
 
5.8.5 Data analysis 
 
If not otherwise specified, the downstream analysis was performed using the 
1008 differentially expressed genes (DEG, FDR <0.05 and abs|log2(FoldChange)| >1) 
from the bulk RNA-seq experiment when comparing Ly6D+ with TN populations. 
Dimensionality reduction was performed with principal component analysis. 
Average gene expression was centred to zero and PCA plots were generated with the 
ggplot2 v2.1.0 R package. To visualize the degree of cell-to-cell heterogeneity, 
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annotated heatmap of sample pair-wise Pearson’s correlation coefficients was 
produced using the NMF v0.20.6 R package. Eight Ly6D+ cells were not considered 
for subsequent clustering because of their very low transcriptome correlation to any 
other cell, on average less than 0.3 (Fig. 11C left, in results section). Cell clustering 
was performed using the Partitioning Around Medoids (PAM) method implemented 
in the cluster v2.0.4 R package [124]. Gene expression was first centered (mean=0) 
and distances were calculated from cell-to-cell Pearson’s correlation values using the 
Euclidean method. The optimal number of clusters was selected based on silhouette 
plot, which for Ly6D+ corresponded to K=2 (with average silhouette width of 0.10) 
and K=3 for the TN (with average silhouette width of 0.13). Cells with negative 
silhouette width values were excluded while the other 331 cells were assigned to 
one of the 5 groups. Heatmap with Pearson’s correlation coefficients among the 
clustered groups of cells was generated with the top 50% of genes with highest 
variance across analysed dataset (calculated as inter-quartile range) and visualized 
with the NMF v0.20.6 R package. 
Differential gene expression analysis to compare the clustered groups of cells 
was performed using the 14,528 detected expressed genes across the 331 single 
cells with edgeR v3.12.1 [121]. A prior count of 0.5 was added to all gene counts in 
order to minimize the large log-fold changes for genes with small number of counts. 
Genes with FDR <0.05 and abs|log2(FoldChange)| >1 were considered as 
differentially expressed. MA, Volcano, Violin and Scatter plots were produced using 
custom R scripts.  
Gene ontology enrichment analysis was performed with the DAVID v6.7 
bioinformatics database, based on Fisher’s Exact method [122, 123]. Gene ontology 








6.1 EPLM progenitor population can be divided into at least 4 
subpopulations 
 
We have previously characterized an uncommitted and multipotent 
haematopoietic B220+ CD117int CD19- NK1.1- progenitor with combined lymphoid 
and myeloid potential that we have called “Early Progenitor with Lymphoid and 
Myeloid potential” (EPLM) [33]. When describing progenitor cells that apparently 
have multiple lineage potentials, there is a continuing debate concerning whether 
individual cells within the seemingly phenotypically homogeneous population are 
truly multipotent or whether the population contains a mixture of cells each with 
different lineage potentials. With the aim of addressing this question, we decided to 
examine the expression of additional markers known to be associated with different 
haematopoietic lineages. These markers were Ly6D, SiglecH and CD11c. Ly6D 
(Lymphocyte Antigen 6 Complex, Locus D) is a receptor with unknown function used 
as a specification marker for early B-cell stages. Indeed, a Ly6D+ subpopulation of 
CLP has already been shown to have a B-cell bias [125, 126]. SiglecH is an 
immunoglobulin-like lectin receptor expressed on mouse plasmacytoid dendritic 
cells (pDC) that upon binding to sialic acid carbohydrates modulates the secretion of 
type I interferons and is commonly used as a pDC marker [127, 128]. CD11c (integrin 
alpha-X) associates with CD18 (integrin beta-2 chain) forming the complex 
CD11c/CD18 that is the receptor for the complement component iC3b as well as for 
fibrinogen and is also involved in cell-cell interactions during inflammatory 
responses. It is important for monocyte adhesion and is used as a murine marker for 
conventional dendritic cells (cDC) [129]. 
To test the expression of the selected markers, we combined the reported 
EPLM gating strategy to define B220+ CD117int CD19- NK1.1- EPLM and included Ly6D 
and SiglecH. This staining combination resulted in the identification of three EPLM 
fractions (F) both in WT and Flt3Ltg mice. Thus, F1 was Ly6D+ SiglecH-, F2 Ly6D+ 
SiglecH+, and F3 Ly6D- SiglecH- (Fig. 4A,B upper panels).  
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). (A,B) Representative FACS plots of EPLM from the BM (2 femurs) of WT (A) and Flt3Ltg 
mice (B) with the addition of Ly6D and SiglecH identifying three fractions (illustrated as F1, F2 and F3). CD11c 
expression in each of the fractions is shown in the second row. (C) Percentage of CD11c
+
 cells in each EPLM 
fraction from WT (n=5) and Flt3Ltg (n=5) mice. Bars show mean±SEM. (D) Representative FACS plot showing the 
gating strategy for the four EPLM subpopulations from WT (upper panel) and Flt3Ltg (lower panel) mice. (E) 
Summary of EPLM subpopulations as percentages (upper panel) or numbers (lower panel) from WT (n=5) and 










Subsequently, we explored CD11c expression by these three fractions in both 
mouse strains. Results indicated that F1 contained only 5.1±0.5% CD11c+ cells 
whereas F2 were mostly CD11c+ (85.2±2.7%). Interestingly, F3 were heterogeneous 
for CD11c expression, with about one third (28.1±2.7%) being CD11c+ in WT but 
considerably more (43.1±9.1%) in Flt3Ltg mice (Fig. 4A,B lower panels and Fig. 4C). 
This result indicates that F3 can be further subdivided into two CD11c+ and CD11c- 
fractions resulting in four major EPLM subpopulations. In Fig. 4D and in subsequent 
experiments, we represent the 4 EPLM subpopulations in a simplified manner by 
staining for Ly6D in one colour and both SiglecH and CD11c using antibodies 
conjugated with the same fluorochromes in the other. We can thus distinguish the 
four EPLM subpopulations as: the Ly6D+ SiglecH- CD11c- (Ly6D+) single positive 
subpopulation in red, the Ly6D- SiglecH- CD11c- triple negative (TN) in green, the 
Ly6D+ SiglecH+ CD11c+ triple positive in blue. Since this is the only subpopulation that 
contains significant numbers of SiglecH+ cells (Fig. 4A,B upper right cytogram), they 
are referred to as SiglecH+. Finally, the Ly6D- SiglecH- CD11c+ (CD11c+) subpopulation 
is shown in orange (Fig. 4D,E). In the bone marrow of WT mice, EPLM 
subpopulations are present in limited numbers (2.7±0.8x103 Ly6D+ cells, 2.3±0.7x103 
TN cells, 3±0.3x103 SiglecH+ cells, and only 1.1±0.3x103 CD11c+ cells). In marked 
contrast, Flt3Ltg mice contain two orders of magnitude more of each EPLM 
subpopulation (2.4±0.9x105 Ly6D+, 0.7±0.2x105 TN, 1.8±1x105 SiglecH+, and only 
0.5±0.2x105 CD11c+) (Fig. 4E lower panel) with minor modifications in their relative 
frequencies (Fig. 4E upper panel). We have previously shown [109] that Flt3Ltg mice 
had dramatically increased numbers of EPLM and this result shows that all four 
subpopulations are affected almost equally.  
In conclusion, based on the expression of Ly6D, SiglecH and CD11c, the EPLM 
progenitor population can be further subdivided into at least four subpopulations 







6.2 The heterogeneity of EPLM is reflected in different sets of 
potentials for each subpopulation 
 
 We next wanted to assess if the heterogeneous expression of Ly6D, SiglecH 
and CD11c cell surface markers by EPLM reflects distinct developmental potentials. 
Several clonal in vitro culture systems exist to quantify the capacity of progenitor 
cells to differentiate into distinct lineages. These systems use stromal cells and 
addition of exogenous factors known to support differentiation towards a particular 
lineage. Stromal cell clones supporting B lymphopoiesis and/or myelopoiesis are well 
established and extensively used. ST2 stromal cells producing macrophage colony-
stimulating factor (M-CSF) support both B lymphopoiesis and/or myelopoiesis 
although the latter one is favoured [112, 130]. B-cell development from 
haematopoietic progenitors is much more efficient on OP9 stromal cells [113, 131] 
because they are derived from the bone marrow of M-CSF deficient op/op mice 







 for B-cell (A), T-cell (B) or myeloid (C) potentials. EPLM subpopulations were 
sorted from WT (10 pooled mice, upper panels) and Flt3Ltg (2-pooled mice, lower panels) and plated at the 
indicated concentrations on either OP9 stromal cells together with IL-7 (A), OP9-DL1 stromal cells in the 
presence of IL-7 (B), or ST2 stromal cells (C). After 10 days (for OP9 cell cultures) or 15 days (for OP9-DL1 and 
ST2 cell cultures), B-cell, T-cell or myeloid clones were scored using an inverted microscope and, when unclear, 
clone type was confirmed by flow cytometry. TN and CD11c
+
 subsets from WT were plated at only 3 cell 
concentrations due to the limited number of cells. The lowest concentration of the two previous subsets was 
plated in 96 replicates while all the rest in 48. One representative experiment is shown and Table 2 
summarizes the independent experiments performed and indicates the n repetitions for each subpopulation, 
mice and condition. 
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[132]. In the absence of M-CSF, macrophage growth is not supported thereby 
revealing lymphocyte potential [130]. This culture system is normally supplemented 
with IL-7 and/or other cytokines promoting cell growth such as Flt3L or SCF. Even 
though B-cell and myeloid propagation was for a long time successfully achieved in 
monolayer stromal cell cultures, a T-cell system had not been reported. Then, in 
2002 Zuniga-Pflücker and colleagues showed for the first time the efficient and long-
term commitment and propagation of T cells in a simple stromal cell monolayer 
system [114, 133]. Use was made of the well-established OP9 stromal cell line, but in 
addition, since the Delta-Notch system had been identified as instructing T-cell 
lineage choice [134], OP9 cells were transduced with the Notch-ligand Delta-like 1 
(DL1). This generated the OP9-DL1 stromal cell line, which efficiently promoted early 
stages of T-cell development. 
We made use of the above described culture systems and performed a 
limiting dilution (LD) assay in order to examine the B-cell, T-cell and myeloid 
precursor frequencies of the four EPLM subpopulations. For that, we sorted them 
from WT or Flt3Ltg mice and plated graded number of cells with the appropriate 
cocktail of stromal cells and cytokines to support B-cell (OP9 + IL7), T-cell (OP9-DL1 + 
IL7) or myeloid (ST2) differentiation. After 10 days (for OP9 cell cultures) or 15 days 
(for OP9-DL1 and ST2 cell cultures), B-cell, T-cell or myeloid clones were scored using 
an inverted microscope and, when unclear, clone type was confirmed phenotypically 
by flow cytometry. The result of a representative experiment is shown in Fig. 5 and a 
summary of all experiments in Table 2. Under B cell conditions, Ly6D+ and TN 
Table 2. Summary table containing mean frequencies of progenitors with B-cell, T-cell and myeloid potential. 













n 11 6 7 8 4 5
mean	freq 1	in	6.4 1	in	38 <	1	in	99 1	in	11 1	in	4.3 <	1	in	500
n 4 3 6 3 2 3
mean	freq <	1	in	500 <	1	in	500 1	in	14 <	1	in	500 <	1	in	500 1	in	30
n 7 3 3 6 3 4
mean	freq 1	in	34 1	in	55 1	in	25 1	in	70 1	in	8.6 1	in	15
n 1 1 1 3 3 3







subpopulations generated colonies, thus revealing B-cell potential. The B-cell 
precursor frequency was higher in the Ly6D+ cells (about 1 in 5) than in the TN 
(about 1 in 20) and overall greater for both subpopulations in WT mice compared 
with their respective counterparts in Flt3Ltg mice (1 in 12 for Ly6D+ and about 1 in 90 
for TN) (Fig. 5A). CD11c and SiglecH+ subpopulations did not generate colonies either 
under B-cell or T-cell conditions (Fig. 5A,B). Ly6D+ and TN cells from WT mice 
generated T cells at low frequencies whereas in Flt3Ltg mice, frequencies were 
notably increased (Fig. 5B). When EPLM subpopulations were plated on ST2 stromal 
cells, the Ly6D+ subpopulation did not generate myeloid clones, whereas all other 
EPLM subpopulations, from either WT or Flt3Ltg mice, possessed myeloid potentials 
although at different frequencies (Fig. 5C). Therefore, each EPLM subpopulation has 
different sets of potentials. Whereas Ly6D+ cells are lymphoid restricted, TN show 
trilineage developmental potential. The SiglecH+ and CD11c+ subpopulations do not 
show lymphoid potential and as their cell-surface marker profile suggests, they could 
be (at least a fraction of them) already committed to the pDC and cDC fates 
respectively. Since in our laboratory we are mostly interested in studying the 
lymphoid development of EPLM, for the rest of the project we focused on the Ly6D+ 
and TN subpopulations.  
We therefore tested the in vivo capacity of Ly6D+ and TN progenitors to 
reconstitute the B- and T-cell compartments of lymphopenic mice. The two EPLM 
subpopulations were sorted from WT or Flt3Ltg mice and equal numbers (4x103 from 
WT and 2x104 from Flt3Ltg) transferred into sub-lethally irradiated Rag2-deficient 
recipient mice [110]. Rag2-deficient mice lack mature B and T lymphocytes due to 
their inability to initiate V(D)J rearrangement. Therefore, the developmental stages 
observed after antigen receptor rearrangement are generated from donor cells. 
Flow cytometry of the spleen at 3 weeks following transfer revealed that B-cell 
compartments were significantly reconstituted in all mice. Both Ly6D+ and TN 
progenitors either from WT or Flt3Ltg generated CD19+ IgM+ B cells (Fig. 6A,C). 
Additional analysis of the spleen CD19+ cells revealed the presence of both CD21high 
CD23- marginal zone B cells (MZB) and CD21int CD23+ follicular B cells (FB) (Fig. 6A 
lower panels). Therefore, although TN cells present less B-cell precursor frequency in 
vitro, both populations have in vivo B-cell developmental potential. Analysis of the 
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Figure 6. Reconstitution of B- and T-cell compartments in sub-lethally irradiated B6 Rag2-deficient mice with 
Ly6D
+
 or TN cells from WT or Flt3Ltg mice. (A) CD19 versus IgM expression on spleen cells 3 weeks after 
transfer of 4x10
3
 WT derived (upper panels) or 2x10
4
 Flt3Ltg derived (lower panels) Ly6D
+
 and TN 
subpopulations. Also CD21 and CD23 expression on gated CD19
+
 spleen cells are shown. (B) CD4 and CD8 
expression on thymocytes 3 weeks after transfer of 4x10
3
 WT derived (upper panels) or 2x10
4
 Flt3Ltg derived 
(lower panels) Ly6D
+













 (D) populations presented as 
frequency of live cells. Ly6D
+
 WT (n=5), TN WT (n=4), Ly6D
+
 Flt3Ltg (n=5), TN Flt3Ltg (n=5). Shown as 
mean±SEM. 
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thymus showed that, in line with the in vitro observations, cells derived from Flt3Ltg 
were much more efficient at reconstituting the thymus than those from WT mice 
(Fig. 6B,D). Thus, WT derived progenitors could only reconstitute the thymus of one 
out of nine mice whereas progenitors from Flt3Ltg mice reconstituted seven out of 
ten animals (Fig. 6D). Comparing the two EPLM subpopulations, in WT mice only the 
Ly6D+ subpopulation had any T cell reconstitution potential (1/5 vs 0/5) whereas in 
Flt3Ltg mice, both subpopulations had quite robust reconstitution potential (4/5 vs 
3/5) (Fig. 6D). In the T-cell reconstituted thymus, we observed normal levels of CD4+ 
CD8+ double positive (DP), and CD4+ or CD8+ single positive T cells. Simultaneous 
staining for TCRβ indicated that, like in the normal thymus, TCRβ expression on DP 
was lower compared to that on CD4+ cells, and that the CD8+ population contained a 
mixture of TCRβ+ and TCRβlow “immature” CD8+ cells (Fig. 6B). Moreover, CD4- CD8- 
double negative (DN) thymocytes were largely TCRβ- and only a small fraction was 
TCRβ+. Interestingly, although Ly6D+ Flt3Ltg cells showed higher in vitro T cell 
potential (Fig. 6A,B lower panels), they reconstituted better the B-cell than the T-cell 
compartment.  
 
6.3 Ly6D+ EPLM has a lymphoid whereas TN a myeloid genetic 
signature 
 
In order to characterize EPLM subpopulations at the molecular level, we 
performed gene expression profiling (RNA-seq) of bulk populations of Ly6D+ and TN 
EPLM subpopulations as well as CD117+ CD19+ Pro-B cells from Flt3Ltg mice. We 
included the latter population as an already B-cell lineage committed bone marrow 
population and thus downstream of EPLMs. Ly6D+ and TN were sorted as indicated 
in Fig. 4D. All populations were sorted four separate times from the pooled bone 
marrow of two 6-8 week-old male Flt3Ltg mice, in which EPLM numbers are 
significantly increased. All samples were processed as explained in Materials and 
Methods and all passed the quality control (Fig. M1 and Fig. M2). Moreover, all 
biological replicates presented high transcriptome correlation (> r=0.990) (Fig. 7). 
Therefore, we proceeded to apply Principal Component Analysis (PCA) to the data 
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and calculated sample pair-wise Pearson’s correlations. The highest variation among 
samples (71.13% reflected in PC1 axis) accounted for their developmental stage; 
with the uncommitted EPLM subpopulation on the left and the committed Pro-B 
cells on the right (Fig. 8A). Pair-wise transcriptome correlation revealed that, in line 
with PCA, Ly6D+ and TN were the two populations with the highest transcriptome 
association (r=0.973) whereas from the two EPLM subpopulations, the Ly6D+ subset 
was the closest to Pro-B cells (r=0.918 Ly6D+/Pro-B versus r=0.886 TN/Pro-B) and 
therefore to the B-cell lineage (Fig. 8B). 
We further explored transcriptome differences by performing differential 
expression analysis and this is summarised in the table in Fig. 8C showing the total 
number of Differentially Expressed Genes (DEG) for each pair-wise comparison as 
well as the number and the fraction corresponding to up-regulated and down-
regulated genes. To be considered as DEG, the gene expression had to be at least 
two times higher or lower in one population compared with the other and this 
change in expression had to be significant (corrected p-value <0.05). A considerable 
Figure 7. Quality of the Ly6D
+
, TN and Pro-B replicates. (A) Scatterplots with individual expression profiles of two 
representative biological replicates for each population. (B) Heatmaps with pair-wise Pearson’s transcriptome 
correlation per population. 
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fraction (21% and 17%) of genes was differentially expressed when comparing Pro-B 
with either Ly6D+ or TN subpopulations respectively whereas only about 6% (1008 
genes) presented a significant change in expression between the two EPLM 
subpopulations (Fig. 8C), thus suggesting again that Ly6D+ and TN cells are more 
related to each other than to Pro-B cells. In addition, the graphical representation of 
the differential expression analysis (volcano plots, Fig. 8D) also revealed that the fold 
changes and significances of DEGs in the Ly6D+vsTN was less (Fig. 8D right panel) 




are closer to the Pro-B cells. (A) Principal component 
analysis and (B) heatmap with pair-wise Pearson’s transcriptome correlation of Ly6D
+
, TN and Pro-B replicates 
and averaged populations respectively. The top 50% of genes with highest variance across analysed dataset 
(calculated as inter-quartile range) were used. (C) Summary table of differential expression analysis containing 
the differentially expressed, up-regulated and down-regulated genes in number and percentage of each pair-wise 
transcriptome comparison. Provided excel file 1 (1_DEGlists_bulkRNAseq) contains the complete lists of DEG. (D) 
Volcano plot (plotted significance against expression ratio) of each pair-wise transcriptome comparison. Each 
dot/star represents a gene. Grey dots: not DEGs; red star: up-regulated genes; blue stars: down-regulated genes. 
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than when they were individually compared with Pro-B (Fig. 8D left and middle 
panels). Interestingly, there was a similar fraction of up-regulated and down-
regulated genes in each comparison, indicating no predominant activation or 




We next investigated in detail the genetic differences between the 
apparently transcriptomically related Ly6D+ and TN EPLM subpopulations. For this, 
we studied the nature of the DEG (Ly6D+ vs TN) by gene ontology (GO) enrichment 
analysis. This analysis revealed that the 500 up-regulated genes in Ly6D+ cells were 
enriched for lymphoid biological processes such as activation, proliferation and 
differentiation of B and T cells, VDJ recombination and immunoglobulin production… 
(Table 3, up). Moreover, the genes that accounted for B-cell related biological 
Table 3. Selection of enriched Biological Processes (eBP) in up-regulated and down-regulated genes of the Ly6D
+
 
versus TN comparison. Complete list in excel file 2 (2_eBP_Ly6DvsTN). 
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processes were highly expressed and most of them within the top 50 of up-regulated 
genes (Fig. 9A, upper panel). Among these, were genes encoding the B-cell related 
transcription factors Pax5, Ebf1 and Pou2af1 (Obf1), the recombinase machinery 
Figure 9. Ly6D
+
 and TN EPLM subpopulations present distinct genetic signatures. (A) MA plot (plotted expression 
ratio against average expression intensity) of Ly6D
+
 vs TN transcriptome comparison. B-cell (upper panel), T-cell 
(middle panel) and myeloid (lower panel) related genes are indicated. Grey labels correspond to characteristic 
genes of both B and T cells. (B) Heatmap of expression of lineage-specific genes indicated in A. The colour 
gradient illustrates the centred gene expression level (log2CPM, mean=0 across all samples and per gene). 
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Rag1 and Rag2, the surrogate light chains VpreB1, VpreB2, VpreB3 and Igll1 (lambda 
5) of the pre B-cell receptor (pre-BCR), the signalling immunoglobulin α (Cd79a) and 
β (Cd79b) chains of the pre-BCR complex, the non-receptor tyrosine kinase Blk 
involved in BCR signaling, the receptor for interleukin-7 Il7r and other lymphoid 
related genes (Dntt, Lax and, as expected, Ly6d itself). Interestingly, although Ly6D+ 
cells were sorted as CD19- cells, mRNA expression of the B cell co-receptor CD19 was 
already detected. Taken together, these results suggest that qualitatively, Ly6D+ cells 
express a B-cell genetic signature characteristic of CD19+ Pro-B cell stage. However, 
quantitatively, the overall expression of these genes is markedly lower than Pro-B 
cells (Fig. 9B). In contrast to B-cell related genes, the genes accounting for T-cell 
related biological processes in the 500 up-regulated genes in Ly6D+ cells presented 
lower expression ratios and variable expression intensities overall (Fig. 9A, middle 
panel). Among these genes were the T-cell transcription factor Bcl11b, the Notch1 
receptor, a master regulator of T-cell commitment whose signaling represses the 
expression of genes related with other lineages, the signalling CD3 zeta chain 
(Cd247) of the T-cell receptor (TCR) complex, genes involved in pre-TCR signalling 
such as Lck (non-receptor tyrosine kinase) Rhoh (related GTP-binding protein) Zap70 
(tyrosine kinase) and Sla2 (Src-like-adapter protein), Trat1 (an adaptor protein that 
stabilizes the TCR/CD3 complex at the surface of T-cells), the tnfsf11 cytokine and 
Nlrc3 (positive regulators of T cell activation), and the inhibitory T-cell related 
receptors Ctla4 and Ctla2b. This T-cell genetic signature is exclusive to the Ly6D+ 
subpopulation (Fig. 9B) and is the “feature” that separates them from both the Pro-B 
and TN cells along the PC2 of the principal component analysis (Fig. 8A). 
Analysis of the 500 down-regulated genes revealed that they were largely 
related with myeloid and innate biological processes such as inflammation, 
phagocytosis, responses to bacteria, yeast and fungi, and macrophage activation 
(Table 3, down). Some key genes accounting for these processes were Mpo, Elane 
and Ctsg (enzymes with microbicidal activity), Prtn3 (a serine protease that degrades 
elastin, fibronectin, laminin, vitronectin, and collagen), the phagocytic Fc receptors 
Fcgr2b, Fcgrt, Fcer1g and Fcgr1, the pathogen recognition receptor Tlr1 (Toll-like 
receptor 1), Gata2 (transcriptional regulator of phagocytosis), Clec7a (involved in 
TLR2-mediated inflammatory responses), the polysaccharide binding protein Lbp and 
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the chemokine receptor Cx3cr1 involved in myeloid leukocyte activation (Fig. 9A, 
lower panel, and B). Therefore, TN cells would appear to present a myeloid genetic 
signature.  
From this transcriptomic analysis, we conclude that i) EPLM subpopulations 
are distinct from one another and are both distinct from Pro-B cells ii) of the two 
EPLM subsets, Ly6D+ cells are closer to Pro-B cells iii) whereas the Ly6D+ subset has a 
largely lymphoid genetic signature, that of the TN subset is more myeloid.  
 
6.4 EPLM subpopulations are developmentally related 
 
 We have seen that Ly6D+ and TN cells have distinct genetic signatures and 
different in vitro developmental potentials. However, they are fractions of the 
original EPLM population. The question arose whether as a population EPLM are 
composed of developmentally unrelated fractions or whether there is a precursor-
product relationship between them. To address this question, we sorted the two 
EPLM subpopulations from Flt3Ltg mice and cultured them in the presence of Flt3L 
and IL-7. An initial number of 5x104 cells were plated and from day 2 to day 6 we 
monitored the emergence of Ly6D+ and CD19+ cells by flow cytometry. We observed 
that, already after 48 hours, almost half of the cells sorted as Ly6D negative (TN), up-
regulated Ly6D (Fig. 10A lower left panel). This indicates that the TN EPLM 
Figure 10. TN subpopulation is the precursor of the 
Ly6D
+
 subpopulation and differentiates into B cells 





 or TN cells from Flt3Ltg supplemented 
with Flt3L and IL-7. From day 2 to day 6 one well 
containing cells from each population was analyzed by 
flow cytometry for Ly6D and CD19 expression (A) and 
the total number of cells was counted to monitor the 
number of CD19
+
 B cells (B). One representative 
experiment is shown out of 3. 
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subpopulation can give rise to the Ly6D+ subset. B cells expressing CD19 were 
detected around day 4 reaching 24% of cells at day 6, whereas by this time, Ly6D 
expression had decreased (Fig. 10A lower panels). In contrast, Ly6D+ cells had 
differentiated into B cells already by day 2 and 75% were CD19+ at day 6 (Fig. 10A 
upper panels). Moreover, the total number of B cells generated from Ly6D+ was 
dramatically higher than those generated from TN cells (Fig. 10B). These results 
indicated that, as observed in the limiting dilution assays, Ly6D+ cells have higher B-
cell precursor frequency and differentiate into B cells with faster kinetics compared 
with TN. The slower kinetics observed in the TN cells indicate that the TN are the 
direct precursors of the Ly6D+ and, therefore, they might first move to the Ly6D+ 
stage before differentiating into B cells.  
 
6.5 Single-cell RNA sequencing reveals distinct degree of molecular 
heterogeneity of Ly6D+ and TN EPLM subpopulations 
 
As a population, the TN subset of EPLM would appear to have multilineage 
developmental potential (Fig. 5) prompting the question whether they are 
composed of a mixture of cells. If this were the case, which fraction of TN EPLM 
constitutes the precursor of the Ly6D+ fraction? Therefore, we further explored the 
heterogeneity of EPLM subpopulations by performing single-cell RNA sequencing. 
Ly6D+ (B220+ CD117int CD19- NK1.1- Ly6D+ SiglecH- CD11c-) and TN (B220+ CD117int 
CD19- NK1.1- Ly6D- SiglecH- CD11c-) were sorted from the same Flt3Ltg mice used for 
the bulk RNA sequencing and utilized for the capture of single cells with the C1 
Fluidigm system. A total of 178 Ly6D+ and 232 TN single cells were captured (Fig. M3 
C) and their subsequent library preparation and sequencing were performed as 
explained in Materials and Methods. During the quality control of the sequenced 
data only cells with more than 60% of mapped reads, at least 2x105 counts and more 
than 800 detected genes were selected for further analysis, resulting in 152 Ly6D+ 
and 213 TN single cells (Fig. M4). In Principal Component Analysis cells did not 
cluster according to the chip they were captured, thus revealing that there was no 
batch effect (Fig. 11A). Instead, in the same PCA with the cells coloured according 
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to their cell type, we found that the first component (PC1 axis) partially segregated 
the TN (on the left) from the Ly6D+ (on the right) with some cells overlapping in the 
middle (Fig. 11B and attached 3D_PCAplot_2), suggesting that the two EPLM 
subpopulations, or at least a fraction, are transcriptionally related. PC2 (Fig. 11B) and 
PC3 (attached 3D_PCAplot_2) showed that Ly6D+ cells are distributed along a single 
pathway that is relatively homogeneous whereas the TN cells are more differently 
distributed and exhibit a branching pattern, thereby indicating that they might be 
more heterogeneous. In order to better address this, we quantified the degree of 
cell-to-cell heterogeneity by calculating the cell pair-wise Pearson’s correlation 
coefficients and generating a correlation heatmap for each cell type (Fig. 11C). Ly6D+ 
single cells showed an overall higher transcriptome correlation (predominant 
yellow/orange colour and a mean correlation value of 0.42, Fig. 11C left) compared 
with the TN single cells (predominant blue colour and a mean correlation value of 
Figure 11. Transcriptomic heterogeneity of TN and Ly6D
+
 EPLM subpopulations by single-cell RNA sequencing. 
(A,B) Principal component analysis of 152 Ly6D
+
 and 213 TN single cells using as gene set the 1008 differentially 
expressed genes from the bulk RNA-seq experiment when comparing Ly6D
+
 with TN populations. Cells are 
coloured according to the chip they were captured (A) or the cell type (B). Dynamic 3D PCA plots are provided in 
the attached documents: 3D_PCAplot_1 and 3D_PCAplot_2. (C) Heatmap with cell-to-cell Pearson’s 
transcriptome correlation of Ly6D
+
 (left) and TN (right) cells calculated with the same gene set as for the PCA. 
Mean correlation value (mean cor) and standard deviation (sd) is shown. 
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0.32, Fig. 11C right). Moreover, Ly6D+ cells showed a seemingly homogeneous 
correlation whereas the TN cells presented clusters of cells transcriptomically related 
to each other (yellow) but very different to the rest (blue). These results indicate 
that the TN EPLM subpopulation has in turn a heterogeneous transcriptome and 
might be composed by a mixture of cells.  
 
6.6 Identification of two Ly6D+ and three TN subgroups with distinct 
genetic signatures 
 
The next question after identifying a heterogeneous subset was to unravel 
how many subgroups did it contain. Therefore, we performed cell clustering using 
the Partioning Around Medoids (PAM) method as explained in Materials and 
Methods. The analysis revealed two robust groups (G1 and G2) of Ly6D+ and three  
(G1, G2 and G3) of TN cells as illustrated in the PCA plot coloured according to the 
subgroups (Fig. 12A and attached 3D_PCAplot_3). Thus, the Ly6D+ population is 
further subdivided into G1 Ly6D+, composed of 56 cells (red) and G2 Ly6D+, 
composed of 82 cells (orange), whereas the TN population is subdivided into G1 TN 
with 85 cells (purple), G2 TN composed of 52 cells (blue) and G3 TN with 56 cells 
(green). In order to explore the degree of similarity or divergence among the 
clustered groups of cells we calculated their pair-wise transcriptome correlation, 
which revealed that the two Ly6D+ subgroups had higher transcriptome association 
(R=0.696) than those observed between any of the TN subgroups (R=0.582 G1/G2, 
R=0.662 G1/G3, R=0.666 G2/G3) (Fig. 12B). Interestingly, the two groups of cells with 
the highest transcriptome correlation are part of different EPLM subpopulations, 
namely the G2 Ly6D+ and G1 TN with R=0.721 (Fig. 12B), thereby suggesting that the 
G1 TN (purple cells in Fig. 12A) group could be the fraction of the TN population 
that, as we have observed in culture, is the precursor of the Ly6D+ cells (circles in Fig. 
12A). Finally, the subgroup having the most distinct transcriptome profile is the G2 
TN (Fig. 12B left column, and blue cells in Fig.12A). 
We further studied genetic differences by applying differential expression 
analysis to the clustered groups of cells. The table in Fig. 12C shows all the 
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comparisons analysed reporting the number and percentage of DEG (FDR <0.05 and 
abs|log2(FoldChange)| >1), up-regulated and down-regulated genes. The complete 
table containing the DEG for each comparison is provided as a supplementary file 
(3_DEGlists_scRNAseq). Less than 1% of the genes were differentially expressed 
when comparing the two Ly6D+ subgroups (Fig. 12C first row) and with overall low 
significance level (Fig. 12D, left). In contrast, comparisons among the TN subgroups 
Figure 12. Cell clustering identifies three TN and two Ly6D
+
 distinct subgroups. (A) PCA with shape according to 
cell type (circles Ly6D
+
, triangles TN) and colour according to the subgroups revealed by PAM clustering method 
(materials and methods). Text boxes indicate the group name and the number of cells. Grey: excluded cells due 
to low correlation or negative width silhouette values as explained in materials and methods. 3D_PCAplot_3 
attached. (B) Heatmap with pair-wise Pearson’s transcriptome correlation of Ly6D
+
 and TN subgroups. Average 
expression across all detected genes was calculated for each of the five cell clusters, and the top 50% of genes 
with highest variance across analysed dataset (calculated as inter-quartile range) were used. (C) Summary table 
of differential expression analysis containing the differentially expressed, up-regulated and down-regulated 
genes in number and percentage of the indicated transcriptome comparisons. Provided excel file 
(3_DEGlists_scRNAseq) contains the complete lists of DEG. (D) Volcano plot (plotted significance against 
expression ratio) of the indicated pair-wise transcriptome comparisons. Each dot/star represents a gene. Grey 
dots: not DEGs; red star: up-regulated genes; blue stars: down-regulated genes. 
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yielded more differentially expressed genes (1-6%, Fig. 12C second to fourth rows), 
and with overall higher significance levels and fold ratios (Fig. 12D). Of note, when 
comparing the two subgroups with the highest transcriptome correlation, namely G2 
Ly6D+ and G1 TN, only 25 genes were differentially expressed with Ly6d, as 
expected, on the top (complete DEG lists in 3_DEGlists_scRNAseq excel file), 
therefore confirming that these two subgroups of cells sorted as two phenotypically 
distinct EPLM subpopulations (Ly6D+ and Ly6D-) are related. 
We next performed a detailed screening based on the DEG lists in order to 
unravel the gene expression patterns of each subgroup. Fig. 13 (A-C) shows a 
collection of genes exclusively or more highly expressed in one of the clustered 
groups of cells. The G1 Ly6D+ red subgroup up-regulates genes (Fig. 13A) related 
with B-cell biological processes (Table 4A). Although we have previously shown that 
the entire Ly6D+ population is lymphoid restricted (Fig. 5) and has a strong B-cell 
genetic signature (Fig. 9A upper panel), single-cell transcriptomic analysis reveals 
that this signature is mostly contained within the red subgroup, as is exemplified by 
CD19 expression (Fig. 13A), a hallmark of B-lymphopoiesis. The G2 TN blue cluster of 
cells up-regulates genes characteristic of the cDC lineage such as the genes encoding 
the α and β chains of the major histocompatibility complex (MHC) class II (H2-Aa, 
H2-Ab1, H2-Eb1), the MHC class II-associated invariant chain (Ii, Cd74), the 
transcriptional co-activator of MHC class II genes (Ciita), the E3 ligase (March1) that 
ubiquitinates the cytoplasmic tail of MHC class II regulating their steady-state level of 
expression, the transcriptional regulators Id2 and Batf3 (expressed by cDC and 
necessary for the development of CD8α cDC) and the integrin Itgb7 related with 
leukocyte migration to mucosal tissues (Fig. 13B). Apart from antigen processing and 
presentation biological processes, the genes up-regulated in the G2 TN cells are also 
involved in actin cytoskeleton organization, leukocyte adhesion, actin 
polymerizations and depolymerisation, protein complex assembly, and regulation of 
cellular component size (Table 4B and lists of DEG (G1vsG2)TN and (G2vsG3)TN in 
excel file 3_DEGlists_scRNAseq). This suggests that the blue group of clustered cells, 
which is the most transcriptionally different to the rest (Fig. 12), might already be 
expressing the intracellular machinery necessary to acquire the dendritic cell 
morphology and the antigen presenting function characteristic of mature cDC. The 
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G3 TN green subgroup mostly up-regulates myeloid related genes (Fig. 13C) involved 
in innate biological processes (Table 4C) characteristic of the entire TN population 
(Fig. 9A lower panel), thus suggesting that this might be the fraction of TN largely 
containing the observed myeloid potential. However, although the G3 TN subset is 
myeloid biased, its genetic signature is not resolved to any specific myelomonocytic 
cell. Some genes such as myeloperoxidase (Mpo) are characteristic of both 
monocyte/macrophages and granulocytes while others are exclusive to granulocytes 
(Elane, expressed in neutrophils) or monocyte/macrophages (chemokine Cx3cr1).  
Figure 13. Distinct genetic signatures of the Ly6D
+
 and TN subgroups. Violin plots with up-regulated or 
exclusively expressed genes in G1 Ly6D
+
 (A), G2 TN (B), G3 TN (C), (G1, G2) Ly6D
+
 and G1 TN (D), or G2 and G3 TN 
(E) subgroups. The median expression level is shown with a line when more than 50% of the cells express the 
indicated gene. G1 Ly6D
+
 (n=56), G2 Ly6D
+
 (n=82), G1 TN (n=85), G2 TN (n=52), G3 TN (n=56). 
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Interestingly, our screening did not find genes exclusively expressed in G2 
Ly6D+ orange cells or G1 TN purple cells. Instead, we observed that these two 
subsets follow the same pattern of expression, meaning that when a gene is 
expressed in one group it is also expressed in the other one (Fig. 13D) or it is down-
Table 4. Selection of enriched Biological Processes (eBP) in up-regulated genes of the G1 Ly6D
+
 (A), G2 TN (B), 
G3 TN (C), G1 TN (D) groups of cells compared with the subgroups indicated in brackets. Complete list in excel file 
(4_eBP_scRNAseq_subgroups). 
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regulated in both (Fig. 13E). Moreover, their pattern of expression is qualitatively 
linked to that of the red subset. Quantitatively, some genes are more highly 
expressed in the G1 Ly6D+ cells (Fig. 13D, upper panels) whereas others in the G2 
Ly6D+ and G1 TN cells (Fig. 13D, lower panels). Among the latter ones, there are T-
cell related genes such as Notch1, Lck, Rhoh, Ctla2a, Ctla2b, Gata3, Lat or Zap70 (Fig. 
13D, lower-left panels), thereby indicating that the orange and purple cells might 
retain T-cell developmental potential. As a conclusion, these two groups have a 
lymphoid genetic profile that is not resolved into any particular lineage, presenting B 
and T enriched biological processes (Table 4D) and co-expressing B-, T- and 
lymphoid-genes (Il7r, Dntt or Lax1, Fig. 13D upper left). Finally, there are genes 
expressed in both green and blue cells (Fig. 13E). These are mostly myeloid related 
genes (Csfr1, Ccr2, Ifi30 or Ctsh) because although the blue cells are some way along 
the cDC lineage, as immature DC they have myeloid properties such as phagocytosis. 
In summary, the single-cell transcriptomic analysis of the Ly6D+ and TN EPLM 
subpopulations reveals that: i) the clustered groups of cells have distinct genetic 
signatures (summarized in Fig. 14A) with a remarkable lympho-myeloid separation 
and ii) the degree of heterogeneity in the entire Ly6D+ and TN populations is 
reflected into their subgroups’ genetic profiles. Thus, both Ly6D+ subsets present a 
lymphoid genetic profile (with the G1 Ly6D+ cell in a more advanced developmental 
stage towards the B-cell lineage), whereas those of the TN present signatures to 
both the lymphoid (G1 TN) or myeloid (G2 and G3 TN) lineages, including some with 
a cDC lineage profile (G3 TN).  
 
6.7 Expression of lymphoid and myeloid genes is mutually exclusive in 
single EPLM cells 
 
We have observed that the same group of cells can co-express genes of 
different lymphoid or myeloid lineages. For instance, the orange G2 Ly6D+ cells 
express both the T-cell master regulator Notch1 and the early B-cell transcription 
factor Ebf1 (Fig. 13A,D), whereas the green G3 TN cells express both the neutrophil 
marker Elane and the macrophage colony-stimulating factor receptor Csf1r (Fig. 
13C,D). In order to elucidate if the previous expression patterns also occur at the 
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single-cell level, we plotted the expression levels of representative pairs of 
transcripts, each characteristic of different lineages. We observed that a large 
Figure 14. Mixed- and opposed-lineage states at the single-cell level. (A) Same PCA plot as in Fig. 12A 
summarizing the genetic signatures of the Ly6D
+ 
and TN subgroups revealed by our bioinformatic analysis. (B-D) 
Scatter plots showing the expression levels in log2FPKM of selected B and T (B), Neutrophil (Neu) and 
Monocyte/Macrophages (Mo/Mc) (C) or Myeloid (Mye) and Lymphoid (Lym) (D) lineage marker pairs in the 
Ly6D
+
 and TN subpopulations. Bottom legend indicates the colour and shape corresponding to each subgroup. 
Dotted vertical and horizontal lines delimit when the transcript of the indicated gene is detected (> 0). 
Percentages within the double-positive area of the plot indicate the fraction of cells co-expressing both genes to 
the number of cells expressing only one gene (top: gene on vertical axis; bottom: gene on horizontal axis). 
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proportion of the Ebf1+ cells also expressed Notch1 (75,6%, Fig. 14B left). The co-
expression level was also high when comparing the immunoglobulin α chain of the 
pre-BCR complex (Igα or Cd79a) with the T-cell tyrosine kinase Lck (75% of the 
CD79a+ and 28.5% of the LcK+ cells, Fig. 14B right) Moreover, when examining 
neutrophil-monocyte/macrophage lineages, a high proportion of single-cells co-
expressed Elane and Csfr1 (76.9% of the Elane+ and 23.3% of the Csfr1+ cells, Fig. 
14C). Therefore, the EPLM progenitor population contains single cells with mixed-
lineage states within the lymphoid (B and T) and myeloid (granulocyte and 
monocyte/macrophage) lineages. 
 
Figure 15. Marker candidates to isolate either the G1 TN (A) or the G1 Ly6D
+
 group of cells (B). PCA plots 
generated as in Fig. 12A. Colour represents the expression level in log2FPKM for each indicated gene per cell. 
Shape indicates the cell type: circles Ly6D
+
, triangles TN. 
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In contrast, we detected distinct lymphoid and myeloid specification for the 
EPLM subgroups, with the cells on the left part of the PCA plot myeloid primed (G2 
and G3 TN), whereas those in the centre (G1 TN and G2 Ly6D+) and on the right (G1 
Ly6D+), lymphoid primed (Fig. 14A). This marked lympho-myeloid separation was 
confirmed at the single-cell level since we did not encounter significant co-
expression of early myeloid (Cebpa and Ctsg) and lymphoid (Rag1 and Il7r) 
specification genes (Fig. 14D). The mutual exclusive expression of lymphoid and 
myeloid genes indicates that the EPLM might be composed of a mixture of cells with 
either lymphoid or myeloid priming and, that the multilineage developmental 
potential observed for the TN EPLM subpopulation is possibly not contained in the 
same single cell.  
 
6.8 Selective markers for each subgroup. TdT the best candidate to 
separate cells with lymphoid from those with myeloid genetic profiles  
 
After identifying selectively expressed markers for each of the clustered 
groups of cells (Fig. 13), we selected the best candidates in order to isolate the 
subgroups of interest and validate their genetic signatures with functional assays. 
We first isolated the G1 TN purple cells since we hypothesized that this TN fraction 
could be the precursor of the Ly6D+ EPLM subpopulation. For that, we performed 
and extensive screening using the PCA plot as a powerful way of interrogating the 
gene expression of any gene across the dataset and the best candidate was the Dntt 
gene (Fig. 15A upper left). In the PCA plot with cells coloured according to the Dntt 
transcript level (expressed in log2FPKM), we observe that all G1 and G2 Ly6D
+ cells 
(circles) are Dntt positive as well as the vast majority of G1 TN cells (purple in Fig. 
13D upper left panel and Fig. 14A) with the exception of the small upper cluster of 
cells (box in the PCA plot in Fig. 15A). The Dntt gene encodes the Terminal 
deoxynucleotidyl Transferase (TdT) enzyme, a non-template polymerase that 
catalyzes the addition of random nucleotides at the junction of rearranged genes of 




We checked the TdT protein expression by intracellular staining of the EPLM 
progenitor population and confirmed by flow cytometry that TdT can split the TN 
(B220+ CD117int CD19- NK1.1- Ly6D- SiglecH- CD11c-) cells into two almost equal 
fractions (50.5% TdT+) and that it is expressed by nearly all (87.8%) Ly6D+ EPLM (Fig. 
16A). Therefore, TdT is potentially an excellent marker to isolate the TN TdT+ cells, 
equivalent to the G2 TN cluster identified in our bioinformatics analysis, and to test if 
their developmental potential matches that of their observed lymphoid genetic 
signature. Unfortunately, TdT is not a cell-surface marker and cannot be directly 
used to sort TdT positive cells by FACS. Moreover, there is no TdT reporter mouse 
available. For that reason, our laboratory is in the process of generating a TdT 
Figure 16. Expression of TdT, CD115 and Ebf1 within the Ly6D
+
 and TN EPLM subpopulations. (A-C, upper 
panels) Representative FACS plot showing expression of TdT (A), CD115 (B) or Ebf1 (C) protein within the Ly6D
+
 
and TN EPLM of Flt3Ltg (A,B) or Flt3Ltg-Ebf1
ihCd2/+ 
(C). (A-C, lower panels) Percentages of TdT (A), CD115 (B) or 
Ebf1 (C) expressing Ly6D
+
 and TN EPLM from Flt3Ltg (n=3, A; n=4, B) or Flt3Ltg x Ebf1
ihCd2/+ 
(n=3, C). Shown as 
mean±SEM. (D) Construct to generate the Ebf1
ihCd2/+ 
reporter mice as reported in [112]. 
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reporter mouse, which will shed light to this and other ongoing projects in the near 
future.  
As an alternative to TdT, we screened for cell surface candidates that would 
enable us to enrich for the G1 TN fraction of cells. The most promising were those 
encoded by Csf1r, Ly6c2 and Ccr2 genes (Fig. 15A), whose expression is mostly 
overlapping with the blue G2 and green G3 TN cells (Fig. 13E and Fig. 14A). 
Moreover, as shown in the PCA plots (Fig. 15A) they are not expressed by exactly the 
same single cells, suggesting that they could be used in combination in order to 
exclude a major fraction of cells belonging to the G2 and G3 TN clusters. We 
attempted several protein surface stainings of the EPLM with individual or 
combinations of CD115 (or CSF-R, encoded by Csf1r gene), Ly6C2 and/or Ccr2 
markers. However, we only detected significant expression of the CD115 cell surface 
protein, with about one third of the TN EPLM subpopulation being CD115+ (Fig. 16B). 
We also wanted to isolate the G1 Ly6D+ red cells in order to validate their B-
cell specification. For that, the two best candidates were the B-cell transcription 
factor Ebf1 and the BCR complex-associated protein α chain Cd79a (Fig. 15B and Fig. 
13A). We had access to the Ebf1ihCd2/+ mice provided by Prof. Meinrad Busslinger and 
co-workers [111]. These mice had been generated by inserting an internal ribosome 
entry sequence (IRES)-hCd2 (ihCd2) reporter gene into the 3’ untranslated region of 
the Ebf1 gene (Fig. 16D). We next crossed the Ebf1ihCd2/+ reporter to the Flt3Ltg mice, 
thereby generating the Ebf1ihCd2/+-Flt3Ltg mice. EPLM staining of the latter mice 
revealed that on average 57.5% of Ly6D+ cells express hCD2 and therefore Ebf1 (Fig. 
16C).  
 
6.9 Excluding CD115+ cells enriches for TN cells with lymphoid profile 
 
In order to assess if the detected fraction of CD115- TN cells possesses the 
lymphoid genetic signature observed in the single-cell RNA sequencing experiment, 
we performed several assays. First, we examined the B-cell, T-cell and myeloid 
precursor frequencies of the two TN (CD115+ and CD115-) fractions. For that, we 
sorted them from Flt3Ltg mice and plated graded numbers of cells with the 




TN fraction contains the lymphoid profile. (A) Limiting dilution analysis of CD115
+
 TN and 
CD115
-
 TN for B-cell, T-cell or myeloid developmental potentials. EPLM subpopulations were sorted from Flt3Ltg 
(2 pooled mice) and plated at the indicated concentrations on either OP9 stromal cells together with IL-7, OP9-
DL1 stromal cells in the presence of IL-7, or ST2 stromal cells. After 10 days (for OP9 cell cultures) or 15 days (for 
OP9-DL1 and ST2 cell cultures), B-cell, T-cell or myeloid clones were scored using an inverted microscope. One 
representative experiment is shown out of 2. (B) Heatmap of expression of lineage-specific genes as in Fig. 9B. 
The colour gradient illustrates the centred gene expression level (log2CPM, mean=0 across all samples and per 





 TN cells from WT mice. Left panel: CD19 versus IgM expression on spleen cells 3 weeks after transfer. 
Also CD21 and CD23 expression on gated CD19
+





 populations presented as frequency of live cells. CD115
-
 TN (n=5). Shown as 
mean±SEM. 
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 explained in results section 2 and Fig. 5). The results indicated that the CD115- TN 
fraction had lymphoid potential, poor B-cell precursor frequency (< 1 in 50) and 
strong T-cell precursor frequency (1 in 7), whereas the CD115+ TN did not (Fig. 17A 
upper and middle panel). Moreover, the latter population possessed considerably 
higher myeloid developmental potential (1 in 2 for CD115+ TN versus 1 in 20 for 
CD115- TN) (Fig. 17A lower panel). Although low, the myeloid potential observed in 
the CD115- TN could be explained because this fraction contains the G1 TN cells as 
well as others of the G2 and G3 clustered groups (Fig. 15A upper-right panel) that 
showed a myeloid genetic signature. We believe that using TdT as a marker we 
would be able to discriminate the cells with myeloid developmental potential.  
The observed lymphoid developmental potential of the CD115- TN cells 
would appear to be in line with their genetic signature, as revealed by bulk RNA 
sequencing. Briefly, we compared the previously sequenced Ly6D+, TN and Pro-B 
populations (Fig. 9) with the newly identified CD115- TN fraction. In Fig. 17B, a 
heatmap generated with the same genes as was shown in Fig. 9B, indicates that the 
CD115- TN subset has a gene expression pattern more similar to the Ly6D+ than the 
entire TN population has to the Ly6D+ cells, especially for T-cell related genes. 
Finally, although the CD115- TN subset had a poor B-cell precursor frequency in vitro, 
they were able to reconstitute the splenic B-cell compartments of Rag2-deficient 
mice (Fig. 17C). This finding shows their in vivo B-cell developmental potential and 
suggests that there might be a factor that is necessary to support B lymphopoiesis 
missing in the in vitro cultures.  
Collectively, these results indicate that the CD115 marker identified by single-
cell RNA sequencing is able, as predicted by the genetic profiles of the clustered 
groups of cells (Fig. 14A), to exclude cells with myeloid precursor frequency and 
thereby enrich for those having lymphoid profiles and being the precursor of the 
Ly6D+ EPLM subpopulation.  
 
6.10 Ebf1 enriches for Ly6D+ cells with B-cell potential  
 
In order to elucidate if the newly identified Ebf1+ Ly6D+ subset is B-cell 
primed as predicted by the single-cell RNA sequencing experiment, we assessed their 
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 in vitro and in vivo developmental potentials. Since the entire Ly6D+ EPLM 
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 for B-cell and T-cell developmental 
potentials. EPLM subpopulations were sorted from Flt3Ltg-Ebf1
ihCd2/+
 (2-pooled mice) and plated at the indicated 
concentrations on either OP9 stromal cells together with IL-7 or OP9-DL1 stromal cells in the presence of IL-7. 
After 10 days (for OP9 cell cultures) or 15 days (for OP9-DL1), B-cell or T-cell clones were scored using an inverted 
microscope. One representative experiment is shown out of 2. (B) Reconstitution of B (left) and T (right) cell 
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the B-cell and T-cell precursor frequencies of the two (Ebf1+ and Ebf1-) Ly6D+ 
fractions by limiting dilution (Fig. 18A). The results indicate that although both 
subsets have in vitro B and T cell developmental potential, the Ebf1+ Ly6D+ fraction 
has a higher B-cell precursor frequency (1 in 5 for Ebf1+ Ly6D+ versus 1 in 21 for Ebf1- 
Ly6D+), whereas the Ebf1- Ly6D+ fraction has a higher T-cell precursor frequency 
(almost 1 in 2 for Ebf1- Ly6D+ versus 1 in 11 for Ebf1+ Ly6D+) (Fig. 18A). These results 
were confirmed by their differential abilities to reconstitute mouse B- and T-cell 
compartments in vivo (Fig. 18B,C). Whereas the Ebf1+ Ly6D+ subset had all the B cell 
reconstitution potential (2/4 vs 0/5), the Ebf1- Ly6D+ were the only cells able to 
reconstitute the thymus with TCRβ+ T cells (2/5 vs 0/4) (Fig. 18C). Overall, the 
genetic profiles of the two Ly6D+ clusters (red and orange in Fig. 14A) predicted by 
single-cell RNA sequencing, and exemplified with the Ebf1 marker, are reflected in 







The identification of two complementary clonogenic hematopoietic 
progenitors, CLP in 1997 [27] and CMP in 2000 [28], with the capacity to 
differentiate into all cells of the lymphoid and myeloid lineages respectively, resulted 
in the so-called “classical” model of haematopoiesis found in most current text 
books. This classical model reflects a hierarchical decision-making process whereby 
early multipotent progenitors make an early and irrevocable decision to differentiate 
towards either the lymphoid or the myeloid lineages. Since then, the classical model 
of haematopoiesis is in constant revision as a consequence of finding numerous 
additional progenitor cell types and alternative routes of differentiation. For 
instance, the identification of the LMPP [35] suggests an earlier branching of the 
megakaryocyte/erythrocyte pathway to the lympho-myeloid lineages, before the 
branching of the two latter lineages, and is supported by several later studies [70, 
135].  Moreover, the irreversible and strict compartmentalization of haematopoietic 
progenitor cells was first challenged by the finding that in WT mice, committed 
precursor B cells regain multipotentiality upon conditional inactivation of the Pax5 
gene [31]. This suggested that there might be a greater degree of developmental 
plasticity in haematopoiesis than previously thought. Subsequently, our laboratory 
detected in the BM of wild type mice a cell with similar properties to the Pax5-/- Pro-
B cells that we called “Early Progenitor with Lymphoid and Myeloid potential” 
(EPLM) [33]. This was an uncommitted and multipotent haematopoietic B220+ 
CD117int CD19- NK1.1- progenitor with combined lymphoid and myeloid 
developmental potential, therefore challenging the lympho-myeloid dichotomy 
supported by the classical model of haematopoiesis.   
In the present study, we have interrogated the multipotentiality of the EPLM 
in detail and assessed its potential heterogeneity. First, we found that EPLM 
expressed heterogeneous levels of three cell surface markers Ly6D, SiglecH and 
CD11c, resulting in subdivision of EPLM into at least four subpopulations (Fig. 4D). 
Moreover, this EPLM subdivision was still present in Flt3Ltg mice, in which the 
numbers of all EPLM subpopulations were significantly increased almost equally 
(about two orders of magnitude, Fig. 4E), thus making the Flt3Ltg mouse a good 
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model to further study EPLM subpopulations. When we assessed the in vitro and in 
vivo developmental potential of individual subsets by limiting dilution and 
reconstitution assays respectively, we observed that EPLM heterogeneity was 
reflected in different sets of potentials. Briefly, SiglecH+ and CD11c+ subpopulations 
could not generate lymphoid cells and, as their cell surface marker profile suggests, 
they could be (at least a fraction) already committed to the pDC and cDC lineages. 
Ly6D+ cells were lymphoid restricted and TN showed trilineage (B, T and myeloid) 
developmental potential (Fig. 5) although with lower B- and T-cell precursor 
frequencies compared with their Ly6D+ counterparts (Fig. 5A,B). Of note, Ly6D+ and 
TN cells from Flt3Ltg mice showed lower B-cell potential but higher T-cell precursor 
frequencies (Fig. 5A,B), as well as increased T-cell reconstitution efficacy in the 
thymus (Fig. 6D). One explanation for this finding could be the lower levels of Pax5 
and Ebf1 B-cell transcription factors detected in Ly6D+ cells from Flt3Ltg mice 
compared to their WT counterparts (von Muenchow et al., Appendix paper 1). 
However, Flt3L is not an instructive factor for B-cell commitment of these 
progenitors. Instead, the main effect of Flt3L is the induction of their proliferation 
(von Muenchow et al., Appendix paper 1). Therefore, it could well be that an 
increased percentage of cycling progenitors results in a decreased fraction initiating 
the B-cell developmental program, thus explaining the proportional reduction of 
Ebf1- and Pax5-expressing Ly6D+ cells and the increased ability of these progenitors 
to give rise to T cells. However, it is important to mention that, in Flt3Ltg mice, the 
total number of B-cell progenitors is not affected due to the general expansion of 
the EPLM compartment (Fig. 4). Since Flt3L is reported to be important for pDC 
development [109, 136, 137] and the EPLM subpopulations might have pDC 
developmental potential, we hypothesize that pDC progenitors might be expanded 
in the transgenic mice, thereby providing an alternative explanation for the reduced 
B-cell potential. Although a clonal assay to assess quantitative pDC precursor 
frequency does not yet exist, it would be of interest to investigate the pDC 
developmental potential of EPLM subpopulations from WT and Flt3Ltg mice. 
Another striking observation from the developmental potential assays was 
that, in spit of the poor in vitro capacity of TN cells to generate B cells (Fig. 5A), they 
were nevertheless able to reconstitute the splenic B-cell compartments of all 
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injected mice (Fig. 6C). This result therefore suggests that in in vitro cultures, there 
might be a factor missing that is necessary to support B lymphopoiesis. The opposite 
was observed for the T-cell potential in that this was more efficient in vitro than in 
vivo (Fig. 5B and Fig. 6D). A key difference in the two experimental systems used to 
determine T-cell potential is the availability of Notch ligands. Whereas the in vitro 
system generates highly sensitive readouts that take advantage of the T-cell lineage-
promoting activity of Notch1 signalling via culturing progenitors on feeder cells 
expressing Notch ligands [138], the intravenous injection system depends on 
progenitors travelling to the thymus prior to receiving Nocth ligand signalling upon 
thymus entry. Experimentally, this limitation could be overcome if progenitors were 
directly injected intrathymically. However, EPLM are progenitor cells residing in the 
bone marrow and therefore it is probable that although Ly6D+ cells show robust in 
vitro T-cell potential, their “default” physiological fate, when no other lineage 
commitment signal, such as Notch ligand, interferes, might be to become a B cell. 
Finally, we observed similar in vivo capacity of Ly6D+ and TN progenitors to 
reconstitute the splenic B-cell compartment (Fig. 6C). To further confirm this, it 
would be worthwhile injecting limiting numbers of progenitors and monitoring their 
reconstitution at different time points. Overall, these results and associated 
discussions raise the fundamental question of which assays truly represent the 
physiological potential of progenitor cells. 
Transcriptomic analysis of the Ly6D+ and TN EPLM subpopulations showed 
that their distinct developmental potentials were supported by differential gene 
expression programs. Thus Ly6D+ EPLM had a lymphoid molecular priming and 
transcriptomic profile closer to committed Pro-B cells, whereas the TN had a more 
myeloid genetic signature (Fig. 9 and Table 3). Even though TN cells up-regulate 
myeloid genes involved in innate biological processes, we were able to demonstrate 
the precursor-product relationship between TN and Ly6D+ EPLM subpopulations, 
with the TN (or at least a fraction thereof) being the precursor of the Ly6D+ 
subpopulation, and therefore explaining the slower kinetics and decreased efficiency 
of the latter progenitor differentiating into CD19+ B cells (Fig. 13). Collectively, the 
previous data reveals that the TN EPLM subpopulation is a lympho-myeloid 
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progenitor, whereas the Ly6D+ EPLM subpopulation is likely to be the direct 
precursor of CD19+ committed Pro-B cells. 
The emergence of high throughput methods enabling the investigation of 
whole-genome or whole-transcriptome profiles from single cells, boosts the existing 
debate regarding the heterogeneity of apparent phenotypically homogeneous 
progenitor cells that have multiple lineage potentials. To shed light onto this active 
debate, by performing single-cell RNA sequencing we provide herein a detailed 
analysis of the heterogeneity of the Ly6D+ and TN EPLM subpopulations. This study 
captured 365 single-cell gene expression snapshots of the Ly6D+ (152) and TN (213) 
transcriptional landscapes. Principal component analysis is a good method to 
visualize and interpret high dimensional data (e.g. 365 single cells x 14814 detected 
genes). This method maximizes the variance of the features (genes in our case). 
Therefore, in order to obtain informative components (or dimensions) in the plots, it 
is common practise to select a subset of the original gene set that contains most of 
the variation among the samples [53, 139, 140]. One strategy is to perform an 
unsupervised selection of, for example, the 50% of genes with the highest variance 
across the analysed dataset, as was done for the visualization of the bulk RNA 
sequencing experiment. However, to analyse the single-cell data we decided to 
concentrate on the 1008 genes that we identified as differentially expressed 
between the Ly6D+ and TN populations. Our reasoning was that this set of genes 
would provide insights into the intra-population variation. This is because the 
population approach obscures molecular heterogeneity by averaging gene 
expression. By analysis of bulk populations, high expression of a particular gene in an 
individual subset will be interpreted as general expression by all cells. As suggested 
by their branching structure in the PCA and their low cell-to-cell transcriptome 
correlation our initial analysis indicated that the TN subset is a more heterogeneous 
population than their Ly6D+ partners (Fig. 11). Moreover, the PAM clustering based 
on the selected subset of genes, partitioned the Ly6D+ into two major clusters 
whereas the TN was subdivided into three robust groups. Of note, Ly6D+ and TN cells 
had not been completely segregated in the PCA (Fig. 11B), thereby suggesting that 
the overlapping cells might be in a related cellular state. This was confirmed by the 
analysis of the two clustered groups corresponding to the convergent area, namely 
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G2 Ly6D+ and G1 TN (Fig. 12A), revealing that they have the highest transcriptome 
correlation among the subgroups (0.721, Fig. 12B) and the lowest number of DEG 
(25, Fig. 12C). Therefore, the G1 TN is likely to be the fraction that we previously 
observed experimentally to be the precursor of Ly6D+ cells. However, our latter in 
silico analysis performed at the whole-transcriptome scale of the G2 Ly6D+ and G1 
TN subgroups, which are sorted as two phenotypically distinct populations, suggests 
that they should be considered as one subset. This finding highlights the limitations 
of accurately defining complete cellular identities by relying on expression of few cell 
surface markers, the so-called “top-down” approach [141]. This notion has been 
manifested in other studies such as when Paul et al. suggested that the standard 
gating for sorting MEP might be better termed erythrocyte progenitor (EP) gating 
[69].  
When performing cell clustering, it is of pivotal importance to investigate the 
nature of the subgroups in order to determine if the cells are clustered as a result of 
stochastic fluctuations of the transcriptome and certain cellular states (e.g. cell cycle 
status or cellular stress), or instead, the clustering reflects gene expression variation 
that might be significant for the biological function being tested [142]. In our case, 
the hypothesis is to ask whether individual EPLM are multipotent or whether as a 
population they are composed of a mixture of cells with distinct linage 
developmental potentials. Therefore, we sought to determine if the clustered groups 
of cells reflect genetic signatures of progenitors from distinct haematopoietic 
lineages. For that, we extended our analysis to all detected genes (14,814) across the 
365 single-cells and examined the DEG and enriched biological processes defining 
each subgroup (Table 4 and supplementary excel file 3_DEGlists_scRNAseq). With 
this approach, we were able to unravel marked genetic biases between EPLM 
indicative of molecular priming towards distinct fates. Whereas the G1 Ly6D+ 
subgroup showed a strong B-cell genetic signature (red Fig. 14A) with robust 
expression of B-cell related genes characteristic of the Pro-B cell stage (Cd79a, Vpreb 
genes, Igll1, Cd19, Ebf1 or Blnk Fig. 13A) and B-cell enriched biological processes 
(Table 4A), the G2 TN subgroup, which has the most distant transcriptome, revealed 
a cDC genetic signature (blue Fig. 14A) with consistent expression of genes (H2- 
genes, Cd74, Ciita, Id2 or Batf3 Fig. 13B) and enriched biological processes (Table 4B) 
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either related with antigen processing and presentation or necessary for cDC 
development. The G3 TN subgroup exhibited a myeloid genetic signature (green Fig. 
14A), up-regulating myeloid genes (Mpo, Ctsg, Prtn3, Elane, Cx3cr1, Cebpa or Csfr1 
Fig. 13C,E) related with innate processes (Table 4C). Finally, the G2 Ly6D+ / G1 TN 
subset (orange and purple respectively in Fig. 14A) showed a lymphoid genetic 
signature (Fig. 13D and Table 4D) with a B-cell specification milder to that of the G1 
Ly6D+. Taken together, these results indicate that, as reflected by their central 
location in the PCA, these cells might me in an intermediate state while exhibiting 
promiscuous expression of B- and T-cell genes. Therefore, the previous data suggest 
functional heterogeneity among the EPLM subpopulations and validates single-cell 
RNA sequencing as a powerful technology to dissect molecular heterogeneity of a 
previously considered homogeneous population via generating biologically 
meaningful clusters of cells. In addition, numerous studies have reported the use of 
this technology with similar purposes [46, 53, 57, 67-69, 139, 143-145]. For instance, 
Gren et al. reveal transcriptomic variation within the traditionally classified classical, 
intermediate and non-classical monocytes [67]; Paul et al. report heterogeneity in 
myeloid progenitors [69]; Kowalczyk et al. find extensive transcriptome variability 
among HSCs [145]; and Drissen et al. subdivided the pre-GM population into a 
Gata1+ pre-GM fraction generating mast cells, eosinophils, megakaryocytes and 
erythroid cells and a Gata1- pre-GM subset generating monocytes, neutrophils and 
lymphocytes [139]. These publications challenge the existence of a clonal myeloid 
progenitor generating all innate myeloid immune cell types. 
We also investigated lineage priming at the single-cell level and found a 
significant proportion of single cells co-expressing early B- and T-cell (Fig. 14B) or 
granulocyte and monocyte/macrophage (Fig. 14C) specification genes. This is 
consistent with other studies where mixed lymphoid [126, 146] or myeloid [135, 
147, 148] lineage patterns of gene expression are reported in single cells. However, 
whereas heterogeneity is well studied in myeloid progenitors, we are not aware of 
other reports addressing mixed lymphoid priming at the single-cell level and whole- 
transcriptome scale, thus highlighting the importance of our study. Strikingly, and in 
agreement with other reports [144, 149-151], we did not observe single cells with 
mixed myeloid and lymphoid lineage gene expression profiles (Fig. 14D).             
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Hans-Reimer Rodewald and co-workers made use of an Il7r fate mapping mouse line 
to determine the almost exclusive lymphoid progeny of Il7r expressing cells, thus 
further supporting our findings [149]. Nevertheless, we cannot exclude that, due to 
the “snapshot” nature of the transcriptomic analysis, as well as the medium 
throughput of cells analysed and the medium sequencing depth, we are missing a 
transient and presumably rare intermediate state with promiscuous lympho-myeloid 
gene expression. Previous data suggested that bifurcation of the lymphoid and 
myeloid molecular priming occurs before the EPLM stage. Therefore, the common or 
separate origin of the Ly6D+/G1TN (lymphoid primed) versus the G2/G3TN (myeloid 
primed) EPLM fractions is of interest and requires further investigation. In line with 
our findings, there is an increasing body of evidence supporting the notion that 
priming occurs much earlier in development than previously thought. Indeed, 
expression of lineage-affiliated genes has been reported as early as in the HSC stage, 
with various analyses indicating biases at the apex of haematopoiesis [135, 144, 152-
158], thereby suggesting that the cellular output of the multipotent early 
progenitors is small [135]. 
One key aspect of single-cell RNA sequencing studies is the identification of 
markers representative of the identified clusters of cells in order to prospectively 
isolate them and perform functional assays to validate the predicted genetic 
signatures. In our study, we found that the reclassification of EPLM subpopulations 
was exemplified by expression of Dntt (encoding TdT), which was expressed in the 
Ly6D+ as well as the vast majority of G1 TN but not in G2 and G3 TN cells (Fig. 15A). 
We believe that TdT reporter mice (being currently generated in our laboratory), will 
provide the exciting opportunity not only to isolate the lymphoid-primed EPLM 
fraction but also to test and demonstrate, as previously suggested [159], if TdT+ 
CD19- cells constitute the earliest lymphoid progenitor in adult mice. Moreover, this 
reporter will be of importance in studies comparing fetal versus adult 
haematopoietic progenitors and to stablish when TdT is first expressed in ontogeny.  
Profiting the power of single-cell RNA sequencing to identify markers in an 
unbiased manner, we performed an extensive screening and found potential 
candidates (Fig. 15A,B). As a proof-of-concept, we made use of Ebf1ihCd2/+ reporter 
mice in order to test the developmental potential of Ebf1+ EPLM (comprising most of 
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the G1 and some G2 Ly6D+ cells). As expected, the Ebf1+ Ly6D+ fraction exhibited 
higher B-cell precursor frequency and in vivo reconstitution potential than the Ebf1- 
Ly6D+ fraction (Fig. 18). This result demonstrates that we can find markers from our 
single-cell transcriptomic analysis that, when tested, successfully predict 
developmental outcome. Although the G1 Ly6D+ fraction has a strong B-cell genetic 
specification and developmental potential, the observed marginal in vitro T-cell 
potential suggests that they are still not restricted to the B-cell lineage. This supports 
the concept that genetic specification precedes commitment [147, 160, 161] and 
that Ebf1 initiates B-cell specification whereas Pax5 acts later to drive commitment 
[126, 160]. Of note, in our single-cell analysis, we barely detected Pax5 expression 
(n=8), which could be due to the insufficient sequencing depth to detect low 
expressing transcripts, or the use of Flt3Ltg mice (in which Pax5 is lower at the EPLM 
stage, von Muenchow et al. Appendix paper 1). However, even though EPLM are 
sorted as CD19-, we consistently detected Cd19 transcript (n=19). Therefore, we 
propose the herein newly identified G1 Ly6D+ subset as the direct precursor of the 
first B-cell committed stage, namely the CD117+ CD19+ Pro-B cells.  
Additionally, we tested the CD115 cell surface marker (encoded by Csf1r 
gene) identified in our single-cell RNA sequencing experiment and expressed by a 
good proportion of the G2 and G3 TN cells. Interestingly, our molecular and 
functional analysis revealed that compared with the entire TN population, CD115- TN 
had reduced myeloid but enriched lymphoid properties (Fig. 17), thus confirming 
that priming at the molecular level correlates with the immediate differentiation bias 
of EPLM cells. Therefore, our data support intrinsic differentiation potentials through 
differential gene expression programs, although we do not exclude the contribution 
of other factors such as epigenetic regulation or extrinsic cytokine signalling.  
Single-cell transcriptome profiling has already enabled advances to be made 
in a broad variety of fields. However, it implies a subsequent prospective strategy 
which, although useful for this and other research studies [65, 139], depends on the 
identification of cell-surface markers or the existence of reporter mice in order to 
translate the single-cell transcriptome findings. Additional genetic tools and 
integration of different omics analysis will certainly be developed, thus enhancing 
the contribution of single-cell analysis technology to the field of cell lineage 
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determination. Indeed, the first genome and transcriptome sequenced from the 
same individual cell already exists [162], enabling a direct comparison of genomic 
variation and transcriptome heterogeneity. The challenge will be to generate 
methods for RNA and protein measurements without destroying the cell of interest 
in order to relate gene expression with cell behaviour. These measurements will 
require transcriptional and translational reporters combined in single-molecule 
imaging and quantification experiments.   
As a summary, in this thesis, by studying the previously reported multipotent 
and uncommitted B220+ CD117int CD19- NK1.1- EPLM progenitor, we have been able 
to: first divide the EPLM into four subpopulations with distinct lineage biases using 
the “top down” strategy. This is based on the expression of cell surface markers 
(Ly6D, SiglecH and CD11c in our case). Subsequently, we further investigated the 
EPLM heterogeneity using the alternative and complementary “botton up” approach 
[141], in which high-dimensional molecular profiles measured for each single cell are 
used to classify distinct states and types. The latter strategy has revealed that: i) 
Ly6D+ and TN EPLM subpopulations have distinct degrees of molecular and 
functional heterogeneity ii) the Ly6D+ subset is composed of two lymphoid specified 
subgroups with a B-cell priming gradient iii) the TN subset is composed of three 
groups of cells with lymphoid or myeloid genetic signatures, including some cells 
with a cDC lineage profile iv) genetic signatures reveal a remarkable lympho-myeloid 
separation and v) this separation is better exemplified by Dntt instead of Ly6D, 
thereby redefining the initial “top down” classification. Taken together, these results 
indicate that the EPLM is a good example supporting the finding that previously 
characterized multipotent progenitor populations are in fact composed of mixtures 
of cells with differently restricted differentiation capacities. EPLM share their B220, 
CD117 and CD19 phenotype with Pax5-/- Pro-B cell clones that exhibit multilineage 
differentiation capacities. However, despite this phenotypic similarity, we can 
conclude from the analysis of the developmental potential of individual subsets that 
EPLM are in fact distinct from Pax5-/- Pro-B cells [30, 31, 33]. More generally, this 
study illustrates how single-cell expression profiling can be used to identify novel 
subpopulations and cellular intermediates that can then be prospectively isolated 
and characterized in functional assays.  
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Finally, in the context of constant and necessary revisions of the 
haematopoietic schemes, we argue in favour of a revised model of haematopoiesis 
in which lineage priming is initiated as early as at the HSC level and progressively 
increases with development, ultimately giving rise to the differentiated blood cell 
types. Thus, unlike the classical hierarchical and branching model of haematopoiesis, 
we support alternative representations like the pair-wise model (Fig. 2; [41]) where 
the route a progenitor cell will take to arrive at a particular destination is more 
flexible than currently represented. This more flexible model better reflects 
haematopoietic versatility and can potentially accommodate the increasingly 
reported alternative differentiation pathways [36, 70, 139, 158]. However, our 
findings suggest a revision of the CLP/EPLM continuum arch of the pair-wise model. 
Now we know that the lymphoid priming of the EPLM resides in the TdT+ fraction 
(herein identified as the Ly6D+ as well as the G1 TN EPLM subpopulations), and 
therefore this is the fraction of EPLM that should be placed directly downstream of 
CLP rather than the entire EPLM population [33]. The location of the other EPLM 
fractions in the above scheme has yet to be defined and requires further 
investigation. Moreover, haematopoiesis seems to occur through a process of 
“graded commitment” [69, 135] and this is consistent with our finding of an 
increasing degree of B-cell priming within EPLM subsets (G2 Ly6D+ / G1 TN < G1 
Ly6D+). How to illustrate the global haematopoietic process of “graded 
commitment” in the revised models of haematopoiesis remains an exciting challenge 
for the near future. Ultimately, this thesis makes a significant contribution to the 
study of the phenotypic and genotypic heterogeneity and lineage priming of 
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Hematopoietic cells are continuously generated throughout life from 
hematopoietic stem cells, thus making hematopoiesis a favorable system to study 
developmental cell lineage commitment. The main factors incorporating 
environmental signals to developing hematopoietic cells are cytokines, which 
regulate commitment of hematopoietic progenitors to the different blood lineages 
by acting either in an instructive or a permissive manner. Flt3-ligand (FL) and 
Interleukin-7 (IL7) are cytokines pivotal for B cell development, as manifested by the 
severely compromised B cell development in their absence. However, their precise 
role in regulating B cell commitment has been the subject of debate. In the present 
study we assessed the rescue of B cell commitment in mice lacking IL7 but 
simultaneously over-expressing FL. Results obtained demonstrate that FL over-
expression in IL7 deficient mice rescues B cell commitment, resulting in significant 
Ebf1 and Pax5 expression in Ly6D+CD135+CD127+CD19- precursors and subsequent 
generation of normal numbers of CD19+ B cell progenitors, therefore indicating that 
IL7 can be dispensable for commitment to the B cell lineage. Further analysis of 
Ly6D+CD135+CD127+CD19- progenitors in IL7- or FL-deficient mice over-expressing 
Bcl2, as well as in IL7-transgenic mice suggests that both FL and IL7 regulate B cell 
commitment in a permissive manner; FL by inducing proliferation of 















Hematopoiesis, the generation of all blood cells from hematopoietic stem 
cells (HSC), takes place continuously in the adult bone marrow. Accumulating 
evidence suggests that HSC generate the different hematopoietic lineages via oligo-
potent progenitors having limited self-renewal capacity and restricted 
developmental potentials. Activation of lineage-specific gene transcription in these 
progenitors eventually leads to their commitment to a particular lineage. Cytokines 
are the most prominent environmental factors regulating hematopoietic lineage 
commitment, doing so by acting either in an instructive or a permissive manner (1). 
In the instructive model, cytokines induce a signaling cascade in progenitors leading 
to the initiation of a lineage-specific gene program, typically through up-regulation 
and/or activation of transcription factors, eventually resulting in commitment to a 
particular lineage. In contrast, the permissive model advocates that commitment of 
progenitors to different lineages occurs in a cell-autonomous, stochastic manner, 
with cytokines acting as a selection rather than a commitment factor, promoting the 
survival and/or proliferation of a specific lineage at the expense of other lineages 
originating from the same progenitor. Elucidating the precise mode of action of 
cytokines is technically challenging and therefore the instructive versus permissive 
roles of cytokines is hotly debated (2-4). Although the permissive model was favored 
in the past, recent data provide solid evidence for the instructive action of several 
cytokines including M-CSF, G-CSF, EPO and Flt3-ligand (5-8). However, our 
understanding of how cytokines regulate hematopoiesis remains elusive, as different 
cytokines can act in various ways and their function might be cell-context dependent 
(9). Moreover, most studies to date have addressed cytokine regulated myeloid 
differentiation with relatively little information on lymphoid lineage commitment.  
 That Interleukin-7 (IL7) is a crucial cytokine for B cell generation is 
demonstrated by the dramatic defect in B cell generation in mice lacking either the 
cytokine (10) or its receptor (11). Interestingly, while human B cell progenitors are 
also responsive to IL7 (12), disruption of IL7 signaling caused by mutations does not 
ablate B cell development in man (13, 14). IL7 was initially identified as a growth 
factor for B cell progenitors (15) and early studies demonstrated that in vivo over-
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expression of the pro-survival gene Bcl2 did not rescue B cell development in the 
absence of IL7 signaling suggesting that IL7 acts in an instructive manner in B cell 
commitment (16, 17). The subsequent findings that uncommitted Common 
Lymphoid Progenitors (CLP) from Il7-/- mice lacked expression of the transcription 
factor Early B-cell Factor 1 (Ebf1) (18) and that Ebf1 over-expression partially 
restored B cell generation from these CLP (19), led to the hypothesis that IL7, 
through Stat5 activation, instructs commitment to the B cell lineage by initiating 
Ebf1 expression in uncommitted progenitors. Supporting this hypothesis, a putative 
Stat5 binding site was later identified in one of the Ebf1 promoters (20). However, a 
more recent study has shown that Bcl2 can rescue B cell generation in a Stat5 
conditional knock-out mouse (21). Furthermore, the Ebf1-expressing fraction of CLP 
(Ly6D+ CLP) is dramatically reduced in Il7-/- mice (22), therefore providing an 
alternative possibility for the reduced Ebf1 expression observed in Il7-/- CLP. 
Interestingly, B cell lineage commitment is initiated at the molecular level in 
Ly6D+CD19- progenitors (23). Hence, while the importance of IL7 as a growth factor 
for committed B cell progenitors has been well established, it remains unclear 
whether it instructs oligo-potent progenitors to commit to the B cell lineage through 
Ebf1 and Pax5 up-regulation.  
 Ftl3-ligand (FL), the only known ligand for the Flt3 receptor (CD135), is a 
cytokine important for the generation of many hematopoietic lineages and its 
function has gained much attention as mutations in FL signaling are commonly found 
in Acute Myeloid Leukemias (AML) (24). Committed B cell progenitors do not express 
CD135 since expression of the B cell commitment factor Pax5 leads to its down-
regulation (25). However, upon transplantation, bone marrow progenitors from Flt3-
/- and Flt3l-/- mice reconstitute the B cell compartment poorly (26, 27), and FL was 
found to be essential for maintaining normal numbers of uncommitted B cell 
progenitors (28).  
 Recently, we described a FL-transgenic mouse model (hereafter Flt3Ltg) 
expressing high levels of FL in vivo, which has enabled us to suggest an instructive 
role for FL in early stages of hematopoiesis (8). By breeding these mice with Il7-/- 
mice we herein show that increased FL levels can rescue B cell commitment in 
CD135+CD127+CD19- progenitors and restore early CD19+ B cell progenitor numbers 
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in the absence of IL7 signaling, suggesting a permissive role for IL7 in B cell 
commitment. Further analyses of a combination of mouse genotypes over-
expressing or lacking FL and IL7, as well as the pro-survival gene Bcl-2, have enabled 






Increased in vivo levels of FL rescue B cell commitment in Il7-/- Ly6D+CD19- 
progenitors 
We have previously characterized an uncommitted B cell progenitor with 
combined lymphoid and myeloid potential (Early Progenitor with Lymphoid and 
Myeloid potential – EPLM) (29). EPLM can be further subdivided by SiglecH, CD11c, 
CD115 and Ly6D expression enabling us to identify the Ly6D+SiglecH-CD11c-CD115- 
fraction of EPLM (hereafter Ly6D+ EPLM) as the population containing most B cell 
potential, while being devoid of myeloid potential (Fig. S1B). This EPLM 
subpopulation is identified as Lin-CD19-CD117intB220intLy6D+CD135+CD127+ (Figure 
1A) therefore partially overlapping phenotypically with Ly6D+ CLP (Fig. S1A) and pre-
pro-B cells (30, 31). Ly6D+ EPLM numbers in Il7-/- and Flt3l-/- mice are significantly 
decreased compared to WT; 7-fold for Il7-/- and 13-fold for Flt3l-/- respectively and a 
similar dramatic decrease was observed in Ly6D+ CLP from both mutant mice (Figure 
1B-C). FL deficiency also affected the numbers of Ly6D- EPLM and CLP, while IL7 did 
not (Fig. S1C-D). Therefore, Ly6D+ EPLM/CLP represent the earliest developmental 
stage of the B cell pathway affected by the absence of IL7. 
 We have recently generated a mouse model expressing high in vivo levels of 
FL (8). The progenitor compartment of these mice showed a dramatic increase in 
EPLM and CLP numbers, with their Ly6D+ fractions increased 90-fold and 28-fold 
respectively relative to WT (Figure 1D-E). We crossed Flt3Ltg with Il7-/- mice to assess 
the extent to which increased FL levels could potentially rescue the loss of 
Ly6D+CD19- progenitors in Il7-/- mice. As shown in Figure 2 A-B, in vivo over-
expression of FL leads to a significant increase in Flt3Ltg-Il7-/- EPLM and CLP 
numbers, reaching levels of those in Flt3Ltg mice. Crucially, a full rescue of Ly6D+ 
EPLM and CLP can be seen in these mice, with a striking 470-fold and 31-fold 
increase in numbers compared to their Il7-/- counterparts (Figure 2A-B). 
Furthermore, the numbers of the earliest committed CD19+CD117+ pro-B cells were 
fully restored in Flt3Ltg-Il7-/- mice, showing a 251-fold increase compared to Il7-/- 
(Figure 2C and Fig. S2). However, this rescue was less pronounced in downstream 
CD19+CD117-IgM- and CD19+IgM+ B cell stages, since these cells require IL7 to 
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expand. As a consequence of this rescue in bone marrow B cell development, 
numbers of splenic marginal zone and follicular B cells were significantly increased in 
Flt3Ltg-Il7-/- mice compared to Il7-/- (Figure 2D). While thymic T cell development was 
not rescued in Flt3Ltg-Il7-/- mice (Fig S3), a significant increase in splenic T cell 
numbers was observed (Fig. S4) as a result of their expansion upon FL over-
expression (32). 
To assess whether these rescued Flt3Ltg-Il7-/- Ly6D+CD19- progenitors could 
give rise to B cells in vitro, we sorted Flt3Ltg-Il7-/- Ly6D+ EPLM and plated them at 
limiting dilution on OP9 stromal cells in the presence of IL7. As shown in Figure 3A, 
Flt3Ltg-Il7-/- Ly6D+ EPLM could generate B cells at similar frequencies to their WT and 
Flt3Ltg counterparts, whereas the few Il7-/- Ly6D+ EPLM isolated could not. A rescue 
in Ly6D+ EPLM was also observed when Il7-/- mice were injected with FL (Figure 3E) 
and when plated under the same conditions these rescued Ly6D+ EPLM also showed 
a restored in vitro B cell potential (Fig. S5A). Further, when transplanted into 
irradiated Rag2-/- mice they were able to generate IgM+ B cells (Fig S5B-C).  Thus, 
increased FL levels restore the generation of Ly6D+ progenitors, rather than merely 
expanding the few Ly6D+ EPLM/CLP found in Il7-/- mice. Real-time quantitative PCR 
analysis of Ly6D+ EPLM from Flt3Ltg-Il7-/- mice revealed significant expression of 
Ebf1, Pax5 and Foxo1 transcription factors’ mRNA in the absence of IL7 (Figure 3B). 
Ebf1 expression at the protein level was confirmed by intracellular FACS staining 
(Figure 3C-D). Even though the percentage of Flt3Ltg-Il7-/- Ebf1+Ly6D+ EPLM did not 
reach WT levels, it was similar to the one found in Flt3Ltg mice, which produce IL7. 
Therefore, Ebf1/Pax5 expression and subsequent commitment to the B cell fate can 
occur in the absence of IL7 signaling, arguing against an instructive role of this 
cytokine in B cell commitment. 
CD127 (IL7Rα) is a receptor shared between IL7 and thymic stromal 
lymphopoietin (TSLP), a cytokine capable of rescuing B cell development when over-
expressed in the absence of IL7 (33). Since TSLP is produced by dendritic cells (34), 
which are dramatically expanded in Flt3Ltg mice (8), in vivo FL over-expression could 
lead to increased levels of TSLP thereby rescuing B cell development in Flt3Ltg-Il7-/- 
mice. To investigate this possibility we injected Il7-/- or Il7rα-/- mice with FL as 
described above and assessed the rescue of Ly6D+ EPLM and downstream CD19+ 
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progenitors. FL injections into Il7-/- mice resulted in a significant increase in Ly6D+ 
EPLM and CD19+CD117+ B cell progenitors, comparable to the rescue observed in 
Flt3Ltg-Il7-/- mice (Figure 3E). FL injected Il7rα-/- mice also demonstrated a significant 
rescue of Ly6D+ EPLM and CD19+CD117+ pro-B cells, indicating that the observed 
rescue of B cell commitment in Flt3Ltg-Il7-/- mice is not mediated through the action 
of TSLP. 
 
IL7 promotes survival, but not proliferation, of Ly6D+CD135+CD127+CD19- 
progenitors 
Even though our Flt3Ltg-Il7-/- mouse model suggests that IL7 is dispensable 
for B cell commitment, the dramatic decrease in Il7-/- Ly6D+ EPLM/CLP argues for a 
role of IL7 in the maintenance of this population when FL levels are limiting, by 
promoting either their survival or their proliferation. To investigate the potential role 
of IL7 as a survival factor for Ly6D+CD135+CD127+CD19- progenitors, we crossed Il7-/- 
mice with mice expressing the pro-survival gene Bcl2 (35). Bcl2tg-Il7-/- mice 
demonstrated a minor but statistically significant 2.6-fold increase in Ly6D+ EPLM 
and 2.2-fold increase in Ly6D+ CLP numbers compared to Il7-/- mice (Figure 4A-B). 
Cell cycle stage analysis of Ly6D+ EPLM of these mice indicated that most of the cells 
rescued by Bcl2 are in a quiescent state (Fig. S6) and do not proliferate in response 
to cytokines, thereby compromising to some extent the rescue of these progenitors’ 
numbers. Importantly, when plated on OP9 stromal cells plus IL7, Bcl2tg-Il7-/- Ly6D+ 
EPLM generated B cells at frequencies similar to WT mice (Figure 4C), indicating that 
these rescued Ly6D+ cells had B cell potential. Indeed, when analyzing bone marrow 
CD19+ committed progenitors, we could see a significant 68-fold increase in the 
earliest CD19+CD117+ pro-B cell compartment, compared to Il7-/- (Figure 4D). Due to 
the their quiescent state {Fig. S6 and (36)} and the IL7 dependence of their 
proliferation, Bcl2tg-Il7-/- CD19+CD117+ numbers did not reach WT levels, whereas 
downstream CD19+ immature B cells showed a less pronounced, but significant 
rescue (Figure 4D). In the periphery of these mice, marginal zone and follicular B cell 
numbers were increased, whereas as previously reported (16), T cell numbers were 
rescued (Fig. S7). Therefore, providing an extra Bcl2-mediated survival signal in vivo 
partially rescues Il7-/- Ly6D+CD19- progenitors with B cell potential and restores 
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significantly the generation of CD19+ progenitors. This suggests a role for IL7 in 
facilitating the survival of Ly6D+CD135+CD127+CD19- progenitors. 
 To evaluate the potential proliferative effect of IL7 on 
Ly6D+CD135+CD127+CD19- progenitors, we analyzed a transgenic mouse model in 
which Il7 expression is driven by an MHC Class II promoter, resulting in increased in 
vivo levels of IL7 (37). These mice exhibit a lymphoproliferative phenotype with 
increased numbers of CD19+ B cells (38). In contrast to bone marrow CD19+ cells, 
Ly6D+ EPLM numbers did not increase in response to elevated IL7 (Figure 5A-C). In 
addition, the cell cycle profile of Ly6D+ EPLM remained unaltered in Il7tg mice 
compared to WT (Figure 5D), arguing against a proliferative action of IL7 on these 
progenitors. To exclude the possibility that a proliferative signal by FL present in 
these mice compromised the effect of increased IL7 on the cell cycle status of Ly6D+ 
EPLM, we crossed Il7tg with Flt3l-/- mice. Over-expression of IL7 in vivo did not result 
in a significant increase in Ly6D+ EPLM or CLP numbers in the absence of FL (Figure 
5E and FigS8). In contrast, a 3-fold increase in CD19+CD117+ numbers was observed 
(Figure 5F), in agreement with the proliferative effect of IL7 on CD19+ B cells. This 
resulted in a small, but significant, increase in splenic follicular B cells (Fig. S9). 
Moreover, cell cycle analysis of Il7tg-Flt3l-/- Ly6D+ EPLM showed no significant 
change in their cycling profile compared to their Flt3l-/- counterparts (Figure 5G). 
Therefore, we conclude that while IL7 acts as a proliferative factor for CD19+ 
committed B cells, it does not do so for their Ly6D+CD135+CD127+CD19- precursors. 
 
FL induces proliferation of Ly6D+CD135+CD127+CD19- progenitors 
As evident in Figure 5G, loss of in vivo FL signaling affected the proliferative 
status of Ly6D+ EPLM. Comparison of Ly6D+ EPLM numbers in mice either lacking or 
over-expressing FL showed a 14-fold reduction in Flt3l-/- Ly6D+ EPLM numbers 
compared to WT, while Flt3Ltg Ly6D+ EPLM increased 105-fold (Figure 6A). A similar 
response to FL levels was observed for Ly6D+ CLP (Figure 6A). Cell cycle analysis of 
Ly6D+ EPLM from these mice showed a significant increase in the percentage of Ki67-
DAPI- cells and a decrease in the percentage of Ki67+ cells when FL signaling was 
absent, while Flt3Ltg Ly6D+ EPLM showed the reverse (Figure 6B and Fig. S10). Thus, 
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our data indicate that FL promotes the proliferation of Ly6D+CD135+CD127+CD19- 
progenitors. 
 To evaluate if FL also regulates the survival of Ly6D+CD135+CD127+CD19- 
progenitors, we crossed Flt3l-/- mice with Bcl2tg mice. Thus, Bcl2tg-Flt3l-/- mice 
showed a minor 2-fold increase in Ly6D+ EPLM numbers compared to their Flt3l-/- 
counterparts (1.8-fold for Ly6D+ CLP) (Figure 6C). Nevertheless, the in vitro B cell 
potential of Flt3l-/- Ly6D+ EPLM progenitors was not improved by Bcl2 over-
expression (Figure 6D). Downstream CD19+ progenitors also demonstrated a partial, 
but significant, rescue (Figure 6E). Our analysis of Bcl2tg-Flt3l-/- mice suggests that 
the reduction in Ly6D+CD135+CD127+CD19- progenitors observed in Flt3l-/- mice can 
only be partially explained by a survival role of FL. In contrast, the clear change in the 
numbers and cycling profile of these progenitors in response to the absence or over-
abundance of FL in vivo, as well as the inability of Bcl2 to rescue their in vitro B cell 
potential, points towards proliferation as being the main effector function of FL at 
this developmental stage. 
 
FL does not instruct commitment to the B cell lineage 
The striking rescue in B cell commitment observed in our Flt3Ltg-Il7-/- mice 
could be explained by a potential instructive role of FL when present at high levels in 
vivo. However, increased FL did not result in Ebf1 or Pax5 up-regulation (Figure 3B-
D). Moreover, analysis of Flt3l-/- Ly6D+ EPLM showed that while absence of FL in vivo 
leads to a reduction in the numbers of Ly6D+ EPLM (Figure 1C), it does not 
significantly reduce the percentage of Ebf1+ cells within the population (Figure 7A-B), 
consistent with a permissive rather than instructive role of FL. Finally, the decrease 
in the Ebf1+ fraction of Ly6D+ EPLM upon exposure to high levels of FL was reflected 
in the increased ability of these progenitors to give rise to T cells in vitro, as 
manifested by the high frequency of T cell clone generation when Flt3Ltg Ly6D+ 
EPLM were plated on OP9DL1 stromal cells in the presence of IL7 (Figure 7C). The 
above data suggest that FL does not instruct commitment to the B cell lineage 






Commitment to the B cell lineage is mediated by the expression of Ebf1 and 
Pax5 transcription factors and it is initiated in CD135+CD127+Ly6D+ progenitors prior 
to CD19 expression (30, 31). In Il7-/- mice, this Ly6D+ CLP compartment is significantly 
reduced (22), a finding confirmed in the present study for both CLP and EPLM, a 
B220int/+ population partly overlapping with CLP and pre-pro B cells (Figure 1B-C). 
The proliferative effect of IL7 on committed CD19+ B cell progenitors (38) makes the 
investigation of its role in B cell commitment challenging when using CD19+ cells as 
readout. Hence, we assessed the role of IL7 in B cell commitment by analyzing the 
Ly6D+ CLP/EPLM compartment in different mouse models. Our analysis of Flt3Ltg-Il7-
/-mice showed a complete rescue of Ly6D+ CLP/EPLM numbers in vivo and their B cell 
potential in vitro and in vivo, while Ebf1 and Pax5 were expressed at similar levels to 
Flt3Ltg mice, thereby indicating that IL7 signaling is not required for their up-
regulation at the Ly6D+CD19- stage (Figures 2 and 3). These results suggest that IL7 is 
not acting as an instructive cytokine in B cell commitment by initiating Ebf1 and Pax5 
expression at the CD135+CD127+CD19- stage, as previously hypothesized (18-20), but 
rather as a permissive one. 
 Early investigations had shown that Bcl2 over-expression in the absence of 
IL7 signaling could rescue T cell (39, 40) but not B cell development (16, 17). 
However, a more recent study demonstrated a Bcl2-mediated rescue of CD19+ 
progenitors in conditional Stat5-/- mice, as well as a strong activation of the pro-
survival gene Mcl1 expression by Stat5 (21), therefore suggesting a survival role for 
IL7 in B cell development. Our use of Il7-/- mice instead of Il7rα-/-, which allows the 
assessment of progenitor in vitro B cell potential, and our focus on 
Ly6D+CD135+CD127+CD19- progenitors, has enabled us to confirm the latter findings 
and extend them to the CD19- stage where B cell commitment events are initiated at 
the molecular level. Interestingly, Il7tg mice analysis showed that IL7 indeed acts as 
a proliferative factor for committed CD19+ cells, but not for their CD19- precursors. 
Even in the absence of FL, excess IL7 was unable to significantly increase Ly6D+ 
CLP/EPLM numbers, while it did so for CD19+ B cell progenitors (Figure 5). Hence, we 
propose that the main role of IL7 at the CD135+CD127+CD19- stage is to provide 
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survival signals to the progenitors until they commit to the B cell lineage upon Pax5 
and CD19 expression, after which it additionally induces their proliferation (Figure 
7D). This survival role becomes particularly critical when FL levels are limiting, 
thereby explaining the reduction in Ly6D+ CLP/EPLM seen in Il7-/- mice. Our study, in 
agreement with previous data (21), identifies a common, permissive rather than 
instructive role for IL7 in both B and T cell development (39, 40). 
 The rescue in B cell commitment without active IL7 signaling occurs when FL 
is expressed above physiological levels. Even though a minor role for FL as a survival 
factor for CD135+CD127+Ly6D+CD19- progenitors cannot be excluded, the main effect 
of FL on these progenitors seems to be the induction of their proliferation, as 
suggested by their expansion and their increased cycling upon FL over-expression, 
with the reverse phenotype observed upon loss of FL signaling (Figure 6). Moreover, 
increased FL leads to expansion of Lin-CD117+Sca1+ cells (LSK) (8), thereby increasing 
the developmental input into the CD135+CD127+Ly6D+CD19- progenitor stage. None 
of the mouse models analyzed in the present study gave any evidence for an 
instructive role of FL in B cell commitment. In contrast, excess FL resulted in a 
proportional reduction of Ebf- and Pax5-expressing Ly6D+CD19- progenitors (Figures 
3 and 7). One explanation for this reduction could be the increased percentage of 
cycling Flt3Ltg Ly6D+CD19- progenitors, resulting in a decreased fraction initiating the 
B cell developmental program. Alternatively, another environmental factor, 
responsible for initiation of Ebf1/Pax5 expression and B cell commitment, could be 
the limiting factor in Flt3Ltg mice, thus leading to a smaller fraction of the expanded 
Ly6D+CD19- compartment entering the B cell pathway. Our conclusion is that FL is 
mainly responsible for generating enough CD135+CD127+Ly6D+CD19- progenitors, 
both by inducing their proliferation and by increasing their developmental input 
from the LSK compartment (Figure 7D) (41, 42). As a result, increased levels of FL in 
Flt3Ltg-Il7-/- mice lead to a dramatic increase in CD135+CD127+Ly6D+CD19- progenitor 
numbers, therefore surpassing the need for the survival role of IL7 at this stage and 
resulting in a sufficient fraction of them committing to the B cell lineage. 
 The generation of B cell progenitors in Flt3Ltg-Il7-/- mice is reminiscent of the 
apparent IL7 independency of human B lymphopoiesis, where relatively normal 
numbers of B cells are seen in patients with mutations in components of the IL7 
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signaling pathway (13, 14). However, all patients with such mutations are neonates 
and in neonatal Il7-/- mice, B cell development also takes place (43). Therefore, the 
apparent difference in the IL7 dependency of B cell development between man and 
mouse could actually reflect the corresponding difference between fetal/neonatal 
and adult lymphopoiesis. Our data showing that increased FL signaling can rescue B 
cell commitment in the absence of IL7 could provide a potential explanation for this 
difference. Fetal/neonatal CD135+CD127+CD19- progenitors might be exposed to 
higher levels of FL and/or show higher sensitivity to FL signaling than adult 
CD135+CD127+CD19- progenitors. Indeed, previous studies showed that despite a 
preferable response of fetal B cell progenitors to TSLP, FL signaling remains an 
absolute requirement for fetal B lymphopoiesis (44, 45).  
 The instructive or permissive progenitor regulation of lineage commitment 
by cytokines is a complex process, in which cytokines can initiate developmental 
transcription programs in progenitors. However, the reverse is also true, since the 
particular epigenetic, transcriptional and signaling landscape of a cell can affect its 
response to a cytokine (9). Indeed, while previous analysis of Flt3Ltg mice indicated 
an instructive role for FL in promoting differentiation of multi-potent progenitors 
towards lympho-myeloid and away from erythroid fate (8), our present data show 
that FL acts in a permissive manner for B cell commitment of CD135+CD127+CD19- 
progenitors. In addition, whereas IL7 induces proliferation of committed CD19+ B cell 
progenitors, it does not do so on CD127+CD19- progenitors, suggesting that upon 
commitment to the B cell lineage, changes in the transcription factor and 
intracellular signaling landscape influence the effector function of IL7. Therefore, our 
present data further support the notion of a cell-context dependent cytokine action. 
 The Ebf1/Pax5 up-regulation and subsequent B cell commitment in Flt3Ltg-
Il7-/- mice shown herein raises the issue of the potential extra-cellular regulation of B 
cell commitment. One possibility could be that another environmental signal from 
the bone marrow microenvironment - other than IL7, TSLP and FL - initiates Ebf1 
expression in CD135+CD127+Ly6D+CD19- progenitors resulting in Pax5/CD19 
expression and B cell commitment. Alternatively, as yet uncommitted 
CD135+CD127+Ly6D+CD19- progenitors could express Ebf1 in a cell-autonomous, 
stochastic, manner with some obtaining sufficient Ebf1 to initiate the B cell gene 
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program and eventually commit to the B cell lineage. The intricate transcription 
factor network sustaining B cell commitment through a series of positive feedback 






MATERIALS AND METHODS 
 
Mice 
For breeding and analysis, age- and sex-matched C57BL/6 Flt3l-/- (27), Flt3Ltg (8), Il7-/- 
(10), Il7rα-/- (11), Il7tg (38), and (C57BL/6 x C3H) Bcl2tg (35) mice backcrossed with 
C57BL/6 for at least 5 generations were used at 6–11 weeks of age. All mice were 
bred and maintained in our animal facility under specific pathogen-free conditions. 
Animal experiments were carried out within institutional guidelines (authorization 
number 1888 from cantonal veterinarian office, Basel). 
 
Antibodies, flow cytometry, and sorting 
For analysis, cells were flushed from femurs of the two hind legs of mice. The 
procedure was performed in PBS containing 0.5% BSA and 5mM EDTA. For detection 
of Ebf1 and cell cycle analysis, cells were fixed and permeabilized after cell-surface 
staining using the Foxp3 Fix/Perm buffer set (eBioscience), and subsequently stained 
with PE-conjugated anti-Ebf1 (T26-818) or FITC-conjugated anti-Ki67 (B56) and DAPI, 
according to the supplier’s protocol. Flow cytometry was done using a BD 
LSRFortessa (BD Biosciences) and data were analyzed using FlowJo Software 
(Treestar). For cell sorting, a FACSAria IIu (BD Biosciences) was used (>98% purity). 
 
In vitro limiting dilution assays 
Experiments have been performed as previously described (47). Briefly, OP9 or 
OP9DL1 stromal cells were plated on flat-bottom 96-well plates one day before the 
initiation of co-cultures, at a concentration of 3000 cells per well. The following day 
stromal cells were γ-irradiated (3000 rad) and the sorted progenitor cells were 
added at different concentrations. Cultures were maintained in IMDM medium 
supplemented with 5 × 10–5  M β-mercaptoethanol, 1 mM glutamine, 0.03% (wt/vol) 
primatone, 100 U/mL penicillin, 100 μg/mL streptomycin, 5% FBS and 10% IL7-
conditioned medium. After 14 days in culture all wells were inspected under an 




Quantitative real-time PCR 
RNA extraction was performed using TRI Reagent® (Life Technologies) followed by 
cDNA synthesis using using GoScript™ Reverse Transcriptase (Promega). Real-time 
PCR was performed using SYBR Green PCR Master Mix (Applied Biosystems).  
 
Statistical analysis 
Statistical analysis was performed with Prism 6.0g software (GraphPad Software, 
Inc.). Two-tailed unpaired Student t tests were used for statistical comparisons. If 
not differently indicated, data are presented as mean values ± SD or SEM. n.s. not 
significant or P > 0.05, *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001. 
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Figure 1. IL7 and FL are necessary for the generation of a normal 
Ly6D+CD135+CD127+CD19- compartment. A. FACS plots showing the gating strategy 
used for identification of Ly6D+ EPLM and their percentage of CD135 and CD127 
expression. Lineage staining: SiglecH, CD115, CD11c, NK1.1, Gr-1. B. Representative 
FACS plots of EPLM (upper row) and CLP (lower row) from the bone marrow of WT, 
Il7-/- and Flt3l-/- mice. C. Absolute numbers of Ly6D+ EPLM (upper graph) and CLP 
(lower graph) from the bone marrow of WT (n=13), Il7-/- (n=5) and Flt3l-/- (n=10) 
mice. D. Representative FACS plots of EPLM and CLP from WT and Flt3Ltg mice. E. 
Absolute numbers of total EPLM and CLP (left graphs) and Ly6D+ EPLM and CLP (right 




Figure 2. Increased in vivo FL levels rescue B cell generation in Il7-/- mice. A. 
Representative FACS plots of EPLM (upper panel) and CLP (lower panel) from WT, Il7-
/-, Flt3Ltg and Flt3Ltg-Il7-/- mice. B. Numbers of EPLM (top left), CLP (bottom left), 
Ly6D+ EPLM (top right) and Ly6D+ CLP (bottom right) from the mouse genotypes 
indicated on the x-axes. For each mouse genotype mean±SEM is shown. C. Numbers 
of CD19+CD117+ (top left), CD19+CD117-IgM- (top right) and CD19+IgM+ (bottom) 
bone marrow cells from the mice indicated on the x-axes. For each mouse genotype 
mean±SEM is shown. D. Numbers of CD19+CD21highCD23low marginal zone (left) and 
CD19+CD21+CD23+ follicular (right) B cells in the spleens of WT or mutant mice, as 




Figure 3. Increased in vivo FL rescues B cell commitment in the absence of IL7 
and/or TSLP. A. In vitro limiting dilution analysis of Ly6D+ EPLM B cell potential. 
Ly6D+ EPLM were sorted from WT, Il7-/-, Flt3Ltg and Flt3Ltg-Il7-/- mice and plated at 
the indicated concentrations on OP9 stromal cells together with IL7. One 
representative out of four independent experiments is shown. B. Real-time 
quantitative PCR analysis showing expression of Ebf1, Pax5 and Foxo1 mRNAs in 
Ly6D+ EPLM sorted from the indicated mouse genotypes. Bars show fold expression 
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relative to WT (set as 1). Error bars represent the SEM from 3-6 independent 
experiments. C. Representative FACS plots showing expression of Ebf1 protein within 
the Ly6D+ EPLM of the indicated WT or mutant mice. D. Percentages of Ebf1-
expressing Ly6D+ EPLM from WT (n=7), Il7-/- (n=3), Flt3Ltg (n=11) and Flt3Ltg-Il7-/- 
(n=6) mice. Bars show mean±SEM. E. Ly6D+ EPLM (left) and CD19+CD117+ (right) 
numbers from WT (n=5), Il7-/-  (n=5), Flt3Ltg (n=3), Flt3Ltg-Il7-/- (n=5) mice, as well as 
from Il7-/- (n=5) and Il7rα-/- (n=6) mice injected intra-peritoneally with 10 daily doses 




Figure 4. Bcl2 over-expression partially rescues B cell commitment in Il7-/- mice. A. 
Representative FACS plots of EPLM (upper panel) and CLP (lower panel) from WT, Il7-
/-, Bcl2tg and Bcl2tg-Il7-/- mice. B. Numbers of EPLM (top left), CLP (bottom left), 
Ly6D+ EPLM (top right) and Ly6D+ CLP (bottom right) from WT and mutant mice, as 
indicated on the x-axes. For each mouse genotype mean±SEM is shown. C. In vitro 
limiting dilution analysis of Ly6D+ EPLM B cell potential. Ly6D+ EPLM were sorted 
from WT, Il7-/-, Bcl2tg and Bcl2tg-Il7-/- mice and plated at the indicated 
concentrations on OP9 stromal cells together with IL7. One representative out of 
three independent experiments is shown. D. Numbers of CD19+CD117+ (top), 
CD19+CD117-IgM- (middle) and CD19+IgM+ (bottom) bone marrow cells from WT and 





Figure 5. IL7 does not induce proliferation of Ly6D+CD135+CD127+CD19- 
progenitors. A. CD19+CD117+ numbers in bone marrow of WT (n=10), Il7-/- (n=5) and 
Il7tg (n=8) mice. B. EPLM numbers in bone marrow of WT (n=14), Il7-/- (n=7) and Il7tg 
(n=5) mice. C. Ly6D+ EPLM numbers in bone marrow of WT (n=14), Il7-/- (n=7) and 
Il7tg (n=5) mice. D. Cell cycle analysis of Ly6D+ EPLM from WT (n=5) and Il7tg (n=2) 
mice. Graph shows percentages of Ki67-DAPI-, Ki67+DAPI- and Ki67+DAPI+ Ly6D+ 
EPLM. Bars in A, B, C and D show mean±SEM. E. Numbers of EPLM (top left), CLP 
(bottom left), Ly6D+ EPLM (top right) and Ly6D+ CLP (bottom right) from WT and 
mutant mice, as indicated on the x-axes. For each mouse genotype mean±SEM is 
shown. F. Numbers of CD19+CD117+ bone marrow cells from WT and mutant mice, 
as indicated on the x-axis. For each mouse genotype mean±SEM is shown. G. Cell 
cycle analysis of Ly6D+ EPLM from WT (n=5), Flt3l-/- (n=3), Il7tg (n=2) and Il7tg-Flt3l-/- 
(n=3) mice. Graph shows percentages of Ki67-DAPI-, Ki67+DAPI- and Ki67+DAPI+ Ly6D+ 




Figure 6. FL promotes proliferation but not survival of Ly6D+CD135+CD127+CD19- 
progenitors. A. Numbers of EPLM (top left), CLP (bottom left), Ly6D+ EPLM (top 
right) and Ly6D+ CLP (bottom right) from WT (n=14), Flt3l-/- (n=10) and Flt3Ltg (n=9) 
mice. Bars show mean±SEM. B. Cell cycle analysis of Ly6D+ EPLM from WT (n=5), 
Flt3l-/- (n=3) and Flt3Ltg (n=9) mice. Graph shows percentages of Ki67-DAPI-, 
Ki67+DAPI- and Ki67+DAPI+ Ly6D+ EPLM. Bars show mean±SEM. C. Numbers of EPLM 
(top left), CLP (bottom left), Ly6D+ EPLM (top right) and Ly6D+ CLP (bottom right) 
from WT and mutant mice, as indicated on the x-axes. For each mouse genotype 
mean±SEM is shown. D. In vitro limiting dilution analysis of Ly6D+ EPLM B cell 
potential. Ly6D+ EPLM were sorted from WT, Flt3l-/- and Bcl2tg-Flt3l-/- mice and 
plated at the indicated concentrations on OP9 stromal cells together with IL7. E. 
Numbers of CD19+CD117+ (left), CD19+CD117-IgM- (middle) and CD19+IgM+ (right) 
bone marrow cells from WT and mutant mice, as indicated on the x-axes. For each 




Figure 7. FL does not instruct Ebf1 expression and B cell commitment. A. 
Representative FACS plots showing expression of Ebf1 protein within the Ly6D+ 
EPLM of WT, Flt3l-/- and Flt3Ltg mice. B. Percentages of Ebf1-expressing Ly6D+ EPLM 
from WT (n=7), Flt3l-/- (n=5) and Flt3Ltg (n=12) mice. Bars show mean±SEM. C. In 
vitro limiting dilution analysis of Ly6D+ EPLM T cell potential. Ly6D+ EPLM were 
sorted from WT and Flt3Ltg mice and plated at the indicated concentrations on 
OP9DL1 stromal cells together with IL7. One representative of four independent 
experiments is shown. D. Schematic model for the permissive role of IL7 and FL 
acting on hematopoietic progenitors and CD19+ committed B-cell precursors. HSC: 
Hematopoietic Stem Cell; LMPP: Lymphoid-primed Multi-Potent Progenitor; CLP: 







Supporting Materials and Methods 
 
Antibodies 
The following antibodies were used for flow cytometry (from BD Pharmingen, 
eBioscience, BioLegend, or produced in house): anti-B220 (RA3-6B2), anti-CD117 
(2B8), anti-CD19 (1D3), anti-NK1.1 (PK136), anti-SiglecH (551), anti-CD11c (HL3), 
anti-CD115 (AFS98), anti-Ly6D (49-H4), anti-CD127 (SB/199), anti-CD135 (A2F10), 
anti-Sca1 (D7), anti-IgM (M41), anti-CD21 (7G6), anti-CD23 (B3B4), anti-CD4 (GK1.5), 
anti-CD8 (53.6.7), anti-TCRβ (H57). 
 
Quantitative real-time PCR 
The primers used were: Ebf1: Ebf1-F: 5’-CAGGAAACCCACGTGACAT-3’; Ebf1-R: 5’-
CCACGTTGACTGTGGTAGACA-3’, Pax5: Pax5-F: 5’ACGCTGACAGGGATGGTG-3’; Pax5-
R: 5’-GGGGAACCTCCAAGAATCAT-3’, Foxo1: Foxo1-F: 5’-AGTGGATGGTGAAGAGCGT-
3’, Foxo1-R: 5’-GAAGGGACAGATTGTGGCG-3’, Actin: Actin-F: 5’-


















Fig. S1. A. CLP FACS staining in WT mice. FACS plots showing the gating strategy used 
for the identification of Ly6D+ CLP. Lineage staining: SiglecH, CD115, CD11c, NK1.1, 
Gr-1. B. In vitro limiting dilution analysis of Ly6D+ and Ly6D- EPLM B cell potential. 
Cells were sorted as shown in Figure 1A and plated at the indicated concentrations 
on OP9 stromal cells together with IL7 A representative of 3 independent 
experiments is shown. C, D. Numbers of EPLM (C) and CLP (D) progenitors in WT 
(n=13), Il7-/- (n=5) and Flt3l-/- (n=10) mice. EPLM were stained as shown in Figure 1A 
and CLP as shown in A. Student’s t test. ***P ≤ 0.001. Bars show mean±SEM. 
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Fig. S2. Rescue of CD19+ bone marrow B cell progenitors in Flt3Ltg-Il7-/- mice. Figure 
shows representative FACS plots for the identification of CD19+CD117+, CD19+CD117-





Fig. S3. Thymic T cell development in Flt3Ltg-Il7-/- mice. A. Representative FACS 
plots showing CD4/CD8 thymocyte staining from 6-8 week old WT, Il7-/-, Flt3Ltg and 
Flt3Ltg-Il7-/- mice (n=4 for each group). B. Total numbers of CD4+ (left panel) and 
CD8+ (right panel) single-positive thymocytes from the mouse genotypes indicated 












Fig. S4. A. Representative FACS plots illustrating T cells in the spleens of WT (first 
row), Il7-/- (second row), Flt3Ltg (third row), and Flt3Ltg-Il7-/- (fourth row) mice. After 
gating on living lymphocytes TCRβ+ cells are further sub-grouped in CD4 and CD8 
positive T cells. B. Representative FACS plots illustrating B cells in the spleens of WT 
(first row), Il7-/- (second row), Flt3Ltg (third row), and Flt3Ltg-Il7-/- (fourth row) mice. 
After gating on living lymphocytes CD19+ cells are further sub-grouped in 
CD21highCD23low marginal zone B cells and CD21+CD23+ follicular B cells. C and D. 
Numbers of splenic CD4+ (C) and CD8+ (D) T cells, stained as shown in A, from WT 
and mutant mice as indicated on the x-axes. ***P ≤ 0.001, ****P ≤ 0.0001. Student’s 
t test; n = 9-15. Data shown above are mean ± SD. 
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Fig. S5. B cell potential of Ly6D+ EPLM cells from Il7-/- mice injected with FL. Il7-/- mice 
were injected with FL (10 daily doses of 10μg for each mouse) and Ly6D+ EPLM were 
sorted from their bone marrows one day after the last injection A. In vitro limiting 
dilution analysis of the B cell potential of FL-injected Il7-/- Ly6D+ EPLM. Cells were 
plated at the indicated concentrations on OP9 stromal cells plus IL7. Flt3Ltg Ly6D+ 
EPLM were used as positive controls. B, C. In vivo B cell potential of FL-injected Il7-/- 
Ly6D+ EPLM. Five thousand Ly6D+ EPLM from FL-injected Il7-/- or Flt3Ltg mice were 
intravenously injected into sub-lethally irradiated Rag2-/- mice. Four weeks after cell 
transfer spleens were analyzed for expression of CD19 and IgM. B. Respresentative 
FACS plots of recipient spleens. C. Numbers of CD19+IgM+ B cells harvested from the 




Fig. S6. Quiescent state of Bcl2-rescued cells in vivo. A. Cell cycle analysis of Ly6D+ 
EPLM from WT (n=5), Bcl2tg, (n=2), Il7-/- (n=2) and Bcl2tg-Il7-/- (n=4) mice. Graph 
shows percentages of Ki67-DAPI-, Ki67+DAPI- and Ki67+DAPI+ Ly6D+ EPLM. *P ≤ 0.05, 
**P ≤ 0.01, ***P ≤ 0.001. Student’s t test. Bars show mean±SEM. B. Representative 





Fig. S7. Bcl2-mediated rescue of splenic T and B cells in the absence of IL7. A. 
Representative FACS plots illustrating T cells in the spleens of WT (first row), Il7-/- 
(second row), Bcl2tg (third row), and Bcl2tg-Il7-/- (fourth row) mice. After gating on 
living lymphocytes TCRβ+ cells are further sub-grouped in CD4 and CD8 positive T 
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cells. B. Representative FACS plots illustrating B cells in the spleens of WT (first row), 
Il7-/- (second row), Bcl2tg (third row), and Bcl2tg-Il7-/- (fourth row) mice. After gating 
on living lymphocytes CD19+ cells are further sub-grouped in CD21highCD23low 
marginal zone B cells and CD21+CD23+ follicular B cells. C. Numbers of splenic CD4+ 
(top) and CD8+ (bottom) T cells, stained as shown in A, from WT and mutant mice as 
indicated on the x-axes. D. Numbers of splenic marginal zone (top) and follicular 
(bottom) B cells, stained as shown in B, from WT and mutant mice as indicated on 
the x-axes.  **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001. Student’s t test; n = 4-9. Data 





Fig. S8. Representative FACS plots of EPLM (upper panel) and CLP (lower panel) from 





Fig. S9. Effect of IL7 over-expression on WT and Flt3l-/- splenic T and B cells. A. 
Representative FACS plots illustrating T cells in the spleens of WT (first row), Flt3l-/- 
(second row), Il7tg (third row), and Il7tg-Flt3l-/- (fourth row) mice. After gating on 
living lymphocytes TCRβ+ cells are further sub-grouped in CD4 and CD8 positive T 
cells. B. Representative FACS plots illustrating B cells in the spleens of WT (first row), 
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Flt3l-/- (second row), Il7tg (third row), and Il7tg-Flt3l-/- (fourth row) mice. After gating 
on living lymphocytes CD19+ cells are further sub-grouped in CD21highCD23low 
marginal zone B cells and CD21+CD23+ follicular B cells. C. Numbers of splenic CD4+ 
(top) and CD8+ (bottom) T cells, stained as shown in A, from WT and mutant mice as 
indicated on the x-axes. D. Numbers of splenic marginal zone (top) and follicular 
(bottom) B cells, stained as shown in B, from WT and mutant mice as indicated on 
the x-axes. ns not significant or P > 0.05, ****P ≤ 0.0001. Student’s t test; n = 3-15. 





Fig. S10. Effect of in vivo FL levels on Ly6D+ EPLM cell cycle. Representative 
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Fetal liver (FL) and bone marrow (BM) derived pro-B cells were propagated 
long-term in stromal cell free cultures supplemented with interleukin-7 (IL-7), stem 
cell factor and FLT3 ligand. Within a week, most cells expressed surface CD19, 
CD79A, λ5 and VpreB antigens and had rearranged immunoglobulin D-J heavy chain 
genes. Both FL and BM pro-B cells reconstituted the B-cell compartments of 
immuno-incompetent Rag2-deficient mice with FL pro-B generating follicular, 
marginal zone (MZB) and B1a B cells, but BM pro-B cells mainly MZB. Reconstituted 
mice generated significant IgM and IgG antibodies to a type II T-independent antigen 
with FL pro-B cell reconstituted mice generating surprisingly high IgG1 titers. Finally, 
we show for the first time that mice reconstituted with mixtures of stromal cell free 
in vitro propagated pro-B and pro-T cells mounted a T-cell dependent antibody 
response. This novel stromal cell free culture system facilitates our understanding of 






In mammals, B cells develop from hematopoietic stem cells (HSCs), 
antenatally from the fetal liver (FL) and postnatally from the bone marrow (BM). 
Various stages of B-cell development are distinguishable by combinations of cell 
surface and intracellular markers, cell cycle profile and rearrangement status of IgH 
and IgL genes [1-4]. B-cell commitment is determined by the transcription factor 
Pax5 [5-7] one of whose target genes is CD19 [8]. The earliest B-cell committed 
precursor, or pro-B cell, proliferates rapidly, is CD19+ CD117+ [1, 9] and has its IgH D–J 
genes rearranged [4]  and are absent in Pax5-deficient [10], Il7 or Il7R gene deleted 
mice [11, 12]. The receptor tyrosine kinases CD117 and CD135 and their 
corresponding ligands, SCF and FLT3L, are important for early B-cell development 
[13-17]. Blocking SCF binding with an anti-CD117 antibody inhibits pro-B cell 
proliferation in IL-7-containing stromal cell cultures [18] and CD135 or FLT3L-
deficient mice have a dramatically reduced BM pro-B-cell compartment [19]. Thus 
Pax5 and cytokines are important for early B-cell development. 
We previously showed that FL-derived pro-B cells could be grown long-term on 
stromal cells and IL-7 [20]. Here we present for the first time that this is possible for 
BM-derived pro-B cells. We have described an early (E) progenitor (P) with lymphoid 
(L) and myeloid (M) developmental potential, called EPLM, in the BM [21]. EPLM are 
B220+, CD117+ but CD19- NK1.1-. When cultured either on OP9 stromal cells plus IL-7 
or without stromal cells but with IL-7, SCF and FLT3L, EPLM from the FL or BM can be 
propagated long-term and differentiate into CD19+ pro-B cells. Moreover, upon in 
vivo transplantation into immunodeficient Rag2 gene deficient hosts, these pro-B 
cells reconstitute a functional B-cell compartment. Finally, when these mice are 
reconstituted with a mixture of in vitro stromal cell free propagated pro-B and pro-T 




Growth of BM pro-B cells long-term 
Using stromal cell-based cultures, only FL-derived pro-B cells could be grown 
long-term [20]. We recently identified a B220+CD117+CD19-NK1.1- BM progenitor 
having lymphoid and myeloid developmental potential, called EPLM [21]; now we 
tested their capacity to generate long-term growing pro-B cells. Thus, 
B220+CD117+CD19-NK1.1- (CD19-) and B220+CD117+CD19+NK1.1- (CD19+) cells from 
FL or BM were sorted (Fig.1A) and plated on OP9 stromal cells plus IL-7. After 6 days, 
cells were harvested every 3 - 4 days and re-plated on fresh stromal cells and IL-7. 
FACS staining 6-7 days after initiation of cultures showed in all cases that the 
cultured cells were >90% positive for CD19 expression and this expression was 
further increased to almost 100% and retained throughout the culture period (data 
not shown and Figure 1D). CD19- (EPLM) cells grew continuously with doubling times 
of about 30hrs, whereas CD19+ cells proliferated for the first 7 days and then died 
(Fig 1B). RNAseq analysis on CD19+ cells derived from CD19- EPLM grown for 12 days 
on OP9 plus IL-7 and freshly-isolated CD19+CD117+ cells similarly grown for 5 days 
revealed that only 83 genes, none of which were B-cell related, were ≥2 fold 
differentially expressed (Table SI). All 44 B cell related genes were similarly 
expressed (Table SII). Gene ontology analysis of the 83 genes did not identify genes 
that explained the growth difference observed. An additional RNAseq analysis of ex 
vivo isolated CD19+CD117+ cells and EPLM derived CD19+ cells maintained on OP9 
stromal cells in the presence of IL-7 for two weeks revealed 3449 differentially 
expressed genes (Table SIII). However, amongst them we could not identify 
particular candidates that might be responsible for the dissimilar growth capacity 
observed.  
FL-derived EPLM grew better than BM-derived EPLM on OP9 with IL-7 
(Fig.1C) with >95% of both becoming CD19+ (Fig.1D) with ~25% BM and >60% FL-
derived cells expressing CD117 (Fig.1D). RT-PCR analysis revealed that both 
expressed CD79a, CD79b, Igll1 (λ5) and Vpreb1 (Fig.1E) and both had undergone DH-
JH rearrangements (Fig.1F). Thus, BM and FL EPLM cultured on OP9 plus IL-7 give rise 
to pro-B cells proliferating for more than three months. 
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Long-term propagation of BM and FL pro-B cells in stromal cell free cultures 
FL pro-B cells propagated on stromal cells plus IL-7 reconstituted the B-cell 
compartment of immuno-deficient mice [20, 29, 30]. However, it is unlikely that pro-
B cells derived from co-culture settings will ever be approved for therapeutic 
purposes. Therefore, we developed a stromal cell free culture system consisting of 
soluble IL-7, SCF and FLT3L. As shown in figure 2A and B, EPLM from FL and BM 
showed very robust growth under these stromal cell free conditions. Indeed, the 
growth rate of BM-derived EPLM was identical under stromal cell and stromal cell 
free conditions (Fig.2A). However, growth of FL EPLM was slightly slower without 
stromal-cell support (Fig.2B). Stromal cell free cultured EPLM became CD19+ with 
~35% BM and >75% FL-derived cells expressing CD117 (Fig.2C and D). Moreover, 
cells cultured without stroma expressed CD79a and b, Igll1 (λ5) and Vpreb1 (Fig.2E) 
and had their IgH chains DH-JH rearranged (Fig.2F). Thus, both BM and FL EPLM 
cultured with IL-7, SCF and FLT3L alone also give rise to long-term proliferating pro-B 
cells. Moreover, as shown for FL-derived pro-B cells [20], BM-derived pro-B cells 
expressing the anti-apoptotic Bcl2 transgene cultured with or without stromal-cell 
support efficiently differentiated into IgM+ B cells upon IL-7 removal (Figure S1). 
 
In vivo B-cell reconstitution by BM or FL EPLM-derived pro-B cells. 
To test whether in vitro-generated FL or BM-derived pro-B cells could 
reconstitute mice, 107 EPLM-derived pro-B from FL or BM of B6 CD45.1 mice 
cultured with or without stroma were transferred into sub-lethally irradiated CD45.2 
B6 Rag2-deficient mice. After 5-10 weeks, FACS analysis of spleen or peritoneal 
cavity (PerC) cells of FL (Fig 3A) or BM (Fig 4A) reconstituted mice showed that 
expression of donor CD45.1+was restricted to CD19+ B cells (first column) and in both 
cases, all CD19+ cells were IgM+ (second column). In figure 3, WT cytograms are 
shown in the first row. Based on CD5 expression, FL-derived pro-B cells propagated 
with or without stroma gave rise to a large fraction of B1a B cells especially in the 
PerC (Fig.3A third column cytograms). As expected, BM-derived pro-B cells 
generated few CD5+ B cells (Fig.4A third column cytograms). Using combined 
expression of CD21 and CD23 to define CD21+/CD23- marginal zone B (MZB) and 
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CD21+/CD23+ follicular B cells (FB) spleen CD19+ B cells derived from FL pro-B cells 
propagated with or without stroma were similar (Fig3A fourth column cytograms). 
Thus 40 – 60% were FB and 30 – 40% were MZB. The CD19+/CD21-/CD23- cells (lower 
left quadrant) most likely represent B1 B cells. Immunohistochemical analysis (Fig 
3B) of reconstituted mice showed the typical B cell follicular structure seen in WT 
mice comprising an outer ring of IgMhigh (green) IgDlow (blue) MZB cells surrounding 
metallophilic macrophages (red) with IgMpositiveIgDhigh FB inside. Mice reconstituted 
with BM pro-B cells cultured by the two methods also showed no obvious 
differences in CD21 and CD23 expression (Fig4A fourth column cytograms). 
However, unlike FL-derived pro-B cells, >70% of BM pro-B cell-derived B cells were 
MZB and only 15 – 20% FB (Fig3B fourth column cytograms). 
Spleens of FL-derived pro-B cell reconstituted mice contained around 5 x 106 
B cells with no difference between cells cultured with or without stroma (Fig.4B). In 
contrast, spleens of mice reconstituted with BM-derived pro-B cells contained only 
0.5 x 106 B cells irrespective of whether they had been propagated with or without 
stroma. Thus FL-derived pro-B cells seem to be much more efficient at reconstitution 
than BM-derived cells. 
To test this more stringently, competitive reconstitution experiments were 
performed. Sub-lethally irradiated CD45.2 B6 Rag2-deficient mice were reconstituted 
with a 1:1 mixture of 5 x 106 CD45.2 FL-derived and CD45.1 BM-derived pro-B cells. 
After 8 weeks, FACS analysis of one representative mouse (Fig 4C) showed that 44% 
of splenocytes were CD19+ of which 97.5% (42.9/44) were FL and 2.5% (1.1/4.4) BM-
derived. Similar results were obtained in more than three independent experiments. 
Thus FL-derived pro-B cells are superior to BM-derived ones also in competitive 
transplantation settings.  
In order to identify genes that might be responsible for these observed 
differences between FL- and BM-derived pro-B cells we performed RNA-sequencing 
analysis of the two populations. This analysis identified 218 genes differentially 
expressed more than 2-fold and with high significance (Table SIV). We identified the 
gene Lin28B, as the one most highly expressed in FL-derived pro-B cells compared to 
BM-derived pro-B (34-fold). It was recently shown that enforced Lin28B gene 
expression in adult HSC converted them functionally into FL HSC [31] and that BM-
 135 
derived pro-B cells gained FL-derived pro-B cell properties [32, 33]. To test whether 
Lin28B expression also influenced reconstitution efficiency, we introduced a MigR1 
retrovirus encoding Lin28B into BM-derived pro-B cells propagated on OP9 stromal 
cells for two weeks. Then 5 x 106 Lin28B transduced and 5 x 106 non-transduced BM-
derived pro-B cells were co-transferred into sub-lethally irradiated Rag2-deficient 
recipients. Only 2% CD19+ cells were found in the spleens of these mice of which half 
expressed Lin28B (GFP) (Figure S2). Thus Lin28B expression did not improve the in 
vivo B-cell generating capacity of BM-derived pro-B cells. However, practically all 
CD19+ cells were IgM+ and > 80% Lin28B+ cells were CD5+, thereby resembling B1 B 
cells. Concerning CD5 expression, Lin28B over-expression also converted BM pro-B 
cells to ones phenotypically resembling FL cells. 
 
Pro-B cell derived B cells mount a T-cell independent immune response 
To test whether the B-cell compartments of Rag2-deficient reconstituted 
mice were functional, 8 weeks after cell transfer they were immunized with the T-
cell independent antigen NIP-Ficoll. Serum anti-NIP titers were determined one 
week before and two weeks after immunization. All reconstituted mice mounted a 
good IgM anti-NIP response with IgM titers comparable to those in immunized wild 
type B6 mice (Fig.5A). Mice reconstituted with BM-derived pro-B cells showed a 
rather low, but significant, IgG anti-NIP response (Fig.5B). However, the IgG anti-NIP 
response of mice reconstituted with FL pro-B cells was as high or even higher than 
wild type B6 mice (Fig.5B). Thus the pro-B cell reconstituted B-cell compartments 
were functional.  
The surprisingly high IgG anti-NIP titers in FL pro-B reconstituted mice 
prompted us to determine their isotypes. Thus, the IgG2A and IgG2B anti-NIP titers 
were low (Fig 5C) and comparable to those in immunized wild type B6 mice whereas 
IgG1 and IgG3 titers were considerably higher. Although high IgG3 titers are observed 
in other T-cell independent responses, switching to IgG1 was thought to be a highly 
T-cell dependent phenomenon requiring IL-4 [34-36]. In addition to T cells, mast cells 
[37, 38], basophils [39], eosinophils [40] and ILC2s [41] may produce IL-4. ILC 
generation is largely dependent on IL-7 and Rag2/common gamma chain (Rag2cγ) 
double-deficient mice are practically devoid of ILCs [42, 43]. Therefore, Rag2 and 
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Rag2cγ double-deficient mice were reconstituted with 107 FL-derived pro-B cells and 
immune responses analyzed as above. Both Rag2 and Rag2cγ double-deficient mice 
showed a very significant IgM and IgG anti-NIP response (Fig.6A and B), similar 
and/or even higher than wild type B6 mice. Moreover, both types of reconstituted 
mice showed a very strong IgG1 and IgG3 anti-NIP response (Fig.6 C and D). Thus the 
IgG class switching observed in immunized reconstituted mice does not seem to be 
regulated by ILCs. 
 
Reconstitution of the adaptive immune system by in vitro-propagated pro-B cells 
and pro-T cells 
Recently, we described a stromal cell free culture system for the long-term 
propagation of pro-T cells that could be used to reconstitute the T-cell compartment 
of T-cell deficient mice [22]. However, reconstituted mice contained few regulatory T 
cells and developed a wasting disease preventable by the co-transfer of mature Treg 
cells or co-transfer of pro-T cells transduced with a retrovirus encoding Foxp3-IRES-
GFP. Simultaneous reconstitution with a mixture of in vitro-propagated pro-B cells 
and a non-transduced and Foxp3 transduced pro-T cells in a 4:1 ratio resulted in T 
but no B-cell reconstitution (not shown). Therefore, sub-lethally irradiated B6 Rag2-
deficient mice were first reconstituted with 107 FL-derived pro-B cells and 4 weeks 
later with 107 pro-T cells of which 2.5 x 106 were Foxp3+. Six weeks after pro-T cell-
transfer, a significant B and T-cell reconstitution was seen in peripheral blood cells 
(data not shown). Because FL pro-B cells partially reconstituted the B-cell 
compartment of B-cell deficient, T-cell proficient, µMt mice and mounted a T-cell 
dependent immune response (Figure S3) we tested whether the established B and T 
cells were functional and could cooperate. Reconstituted mice were therefore 
immunized with the T-cell dependent antigen NIP-OVA. Rag2-deficient mice 
reconstituted with pro-B cells alone were used as controls and serum anti-NIP titers 
determined one week before and two weeks after immunization. No IgM or IgG anti-
NIP response was observed in control pro-B cell-reconstituted Rag2-deficient mice 
(Fig.7A). However, mice reconstituted with both pro-B and pro-T cells mounted a 
strong IgM and relatively weak, but significant, IgG anti-NIP response (Fig.7A). Thus 
the reconstituted adaptive immune system was functional. 
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At 10 – 14 weeks after pro-T cell-transfer, the extent of reconstitution was 
assessed by FACS analysis. In one such mouse, spleen lymphocytes comprised 10% B 
cells, 10% CD8 T cells and 20% CD4 T cells (Fig.7B) with ~10% CD4 T cells expressing 
GFP, indicating they were Tregs. Spleen cell numbers of 7 individual mice 14 weeks 
after pro-T cell-transfer (Fig.7C) show they contained around 3.5 x 106 CD19+ IgM+ B 
cells, 1 x 106 CD8 T cells and 3 x 106 CD4 T cells of which 0.5 x 106 were GFP positive; 
derived from Foxp3 transduced pro-T cells. Thus transfer of in vitro-propagated pro-
B and pro-T cells into Rag2-deficient mice resulted into reconstitution of a small, but 






To our knowledge, this is the first report describing the long-term 
propagation of BM-derived pro-B cells and their use in reconstituting a functional 
immune system in immune-deficient recipients. Pro-B cells from Pax5-/- mice were 
previously shown to have multi-lineage developmental potential [44] and we 
identified an equivalent B220+CD117+CD19-NK1.1- EPLM cell with lymphoid and 
myeloid developmental potential (called EPLM) in the BM of WT mice [21]. Herein 
we show that BM-derived EPLM cultured on OP9 stromal cells plus IL-7 
differentiated into CD19+, CD79a+, CD79b+, Igll1+ and Vpreb1+ pro-B cells with 
rearranged DH-JH genes. Unlike freshly isolated CD19
+ CD117+ pro-B cells, those 
derived from EPLM could be cultured long-term in vitro. Gene expression profiling 
did not reveal an obvious explanation for this difference in growth capacity but could 
possibly be regulated via RNA modification or at the translational level [45-47]. 
To date, long-term growth of pro-B cells required co-culture on stromal cells, 
yet the specific role of stromal cells in this culture system was unknown. Clearly IL-7, 
IL-7R (CD127), SCF and its receptor (CD117) as well as FLT3 and its receptor (CD135) 
all play a role in B-cell development and/or pro-B cell growth [11, 12, 15, 16, 18, 19]. 
Indeed, we now show that EPLMs efficiently grow and differentiate into pro-B cells 
when cultured in the combined presence of IL-7, SCF and FLT3L without contact with 
stromal cells. This indirectly suggests that SCF and FLT3 can substitute for stromal 
cells. 
Pro-B cells maintained on stromal cells plus IL-7 could reconstitute the B-cell 
compartment of immunodeficient mice [20] and herein we extend these findings. 
Both FL and BM EPLM-derived pro-B cells propagated either on stromal cells or 
stromal cell free generated a significant B-cell compartment upon transfer into Rag2-
deficient mice. However, FL-derived pro-B cells were about 40 fold more efficient at 
B-cell reconstitution than their BM-derived partners.  
Although pro-B cells expressing the Lin28B can acquire characteristics of FL-
derived pro-B cells [32] and in vitro-propagated Lin28B-expressing BM-derived pro-B 
cells could generate CD5 positive B cells in vivo, there was no improvement in the in 
vivo-reconstitution capacity of BM pro-B cells.   
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An enlarged MZB compartment is frequently observed in B lymphopenic mice 
[48-52] suggesting that newly-formed B cells first fill the MZB compartment. This 
phenomenon could be due either to a specialized environment within the splenic 
marginal zone or that only B cells expressing certain BCR home to and expand in this 
anatomical location [53]. 
When immunized with the T-independent antigen NIP-Ficoll, all reconstituted 
mice mounted an anti-NIP response indicating their B cell compartments were 
functional.. Mice reconstituted with BM-derived pro-B cells had a slightly lower IgM 
anti-NIP titer than WT mice possibly due to poor B cell reconstitution and showed a 
significant IgG anti-NIP response although still at least 10 fold lower than WT mice. In 
marked contrast, Rag2-deficient mice reconstituted with FL pro-B cells mounted an 
IgM and IgG anti-NIP response that was identical, or even higher than, WT mice 
suggesting that fetal progenitor-derived B cells are the main anti-NIP responders in a 
primary immunization. In B6 mice, the primary anti-NIP antibodies use 
predominantly λ1 light chains [54-56]. The anti-NIP response of pro-B cell-
reconstituted mice was likewise dominated by λ1-containing antibodies (data not 
shown) indicating that the anti-NIP B-cell repertoires in pro-B cell reconstituted mice 
are identical to those of WT mice.  
Surprisingly, FL pro-B cell-reconstituted mice had a high IgG1 anti-NIP 
response an antibody class normally associated with IL-4. Since reconstituted mice 
were devoid of T cells, the question arose which cell type was responsible for IL-4 
production [34-36]. Pro-B cell reconstituted Rag2cγ double-deficient mice, deficient 
in ILCs, also mounted high IgG1 response suggesting that ILCs were not the source of 
IL-4 [42, 43]. Mast cells, basophils and/or eosinophils, could be the source of IL-4 
[37-40]. FL pro-B cells were also able to reconstitute a functional B-cell compartment 
in T-cell containing, B-cell deficient μMt mice (Figure S3). This result might seem 
surprising given that the T-cell compartments in these mice may not be tolerant to 
mature B cells.  
Pro-T cells propagated in vitro under stromal free conditions can reconstitute 
the T-cell compartments of T-cell deficient mice [22]. Here we show that the 
combined transfer of stromal cell free-propagated pro-B and pro-T cells into Rag2-
deficient mice results in the generation of a functional adaptive immune repertoire 
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capable of mounting a T-dependent antibody response. For efficient reconstitution, 
pro-T cell transfer had to be performed 2-3 weeks after the pro-B cell reconstitution 
suggesting that when transferred together, T cells develop that are not tolerant to B 
cells and therefore eliminate them. 
Overall the findings described herein show that progenitor lymphocytes can 
be readily propagated under stromal free conditions in vitro and that these cells can 
be used to reconstitute mice with mature functional lymphocytes. Based on these 
results the establishment of stromal cell free culture systems for human lymphocyte 
progenitors might be of great interest since unlike stromal cell-propagated 
lymphocyte progenitors, stromal cell free propagated cells could be potentially used 
for therapeutic purposes in patients with B and/or T-cell deficiencies. 
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MATERIALS AND METHODS 
 
Mice 
Female C57BL/6 CD45.1 and CD45.2, C57BL/6 Rag2-deficient [23], and C57BL/6 Bcl-2 
transgenic mice [24] with 5–8 weeks of age were used. The appearance of vaginal 
plugs was counted as day 0 of gestation and embryos were taken at day E17.5. All 
mice were bred and maintained in our animal facility under specific pathogen-free 
conditions. Animal experiments were carried out within institutional guidelines 
(authorization numbers 1886 and 1888 from Kantonales Veterinäramt, Basel). 
 
Cell lines, cell culture, and supplements 
The OP9 stromal cell line [25] was cultured as a monolayer in IMDM supplemented 
with 2% FBS, 5 × 10−5 M β-mercaptoethanol, 1 mM glutamine, 0.03% w/v Primatone 
(Quest, Naarden, The Netherlands), and 100 U/mL penicillin. For pro-B cell culture, 
CD117+B220+CD19-NK1.1- cells were sorted from the FL or the femoral BM of adult 
mice and cultured at 104/ml in supplemented IMDM either on a semi-confluent layer 
of 30 Gy -irradiated OP9 stromal cells in the presence of 100U/ml IL-7, or without 
stromal cell support but in the presence of 100U/ml IL-7, 50ng/ml FLT3L, and 
100ng/ml SCF. IL-7 was derived from culture supernatant of J558L cells transfected 
with murine IL-7 cDNA. Polyhistidin-tagged SCF was purified from transfected 
Rosetta pLacI bacteria using Ni-NTA-agarose beads (Qiagen, Venlo, NL). A vector 
expressing a human FLT3L-Fc fusion protein was expressed in Chinese hamster ovary 
cells. The supernatant was passed over a protein A-Sepharose (GE Healthcare, 
Chalfont St. Giles, GB) column in order to purify the protein. Pro T cells were 
cultured as previously described [22]. 
 
Antibodies, flow cytometry, and sorting 
FITC-, PE-, allophycocyanin-, or biotin-labeled mAbs specific for CD117, B220, CD19, 
NK1.1, IgM, Igκ, CD5, CD45.1, CD21, CD23, CD4, CD8α, and TCRβ were either 
purchased from BD Biosciences (Franklin Lakes, NJ, USA) or eBiosciences (San Diego, 
CA, USA), or purified from hybridoma culture supernatants according to standard 
procedures. Staining of the cells was performed as described before [26]. Flow 
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cytometry was done using a FACS Calibur (BD Biosciences) and data were analyzed 
using the CellQuest Pro (BD Biosciences) or FlowJo Software (Treestar). For cell 
sorting, a FACSAria IIu (BD Biosciences) was used (>98% purity). 
 
Transfer of cultured progenitor cells 
Recipient mice were -irradiated using a Cobalt source (Gammacell 40, Atomic 
Energy of Canada, Ltd) 4h prior to reconstitution. The indicated number of pro-B or 
pro T cells was then injected into the tail vein. 
 
Immunohistochemical analysis  
To analyze pro-B-cell derived B-cell localization in the spleen, the 5µm snap frozen 
and acetone-fixed sections were incubated with FITC-labelled anti-IgM (clone M41, 
self-made), APC-labelled anti-IgD (clone 1.19 self-made), and biotinylated anti-
MOMA-1 (Vector, Burlingame, CA), which was revealed with PE-conjugated 
streptavidin (SouthernBiotech, Birmingham, AL). Confocal microscopy images were 
taken with a LSM 510 Meta (Zeiss, Oberkochen, D) and analyzed using the ImageJ 
software and the Fiji image processing package. 
 
NIP-specific antibody responses 
Reconstituted mice were immunized subcutaneously with 100μg NIP-Ficoll or NIP-
OVA in a 1:1 CFA emulsion. Serum IgM and IgG against NIP was analyzed at day 14 
using ELISA as described in [27]. 
 
PCR analyses 
The PCR conditions for amplifying DHJH rearrangements were described elsewhere 
[4, 6, 28]. The primers used were DH 5´-TTCAAAGCACAATGCCTGGCT-3´ and JH3 5´-
GTCTAGATTCTCACAAGAGTCCGATAGACCCTGG-3´. Oligonucleotide primers used for 
CD79A verification from pro-B cDNA were 5´-TGTTTGGGTCCCGGATGCCA-3´and 5´-
CACGCGGAGGTAAGTACCACA-3´, for CD79B 5´-TCTTCTCAGGTGAGCCGGTA-3´and 5´- 
TATGGTTGGCGCTGTCACAT-3´, for IGLL1 5´- AGTAGGACAGACTCTGGGCA-3´and 5´- 
GGCTGACCTAGGATTGTGAGC-3´, for VPREB1 5´-CTCCGGGTCCAAAGATACGAC-3´and 






Statistical analysis was performed with Prism 6.0g software (GraphPad Software, 
Inc.). Two-tailed unpaired Student t tests were used for statistical comparisons. If 
not differently indicated, data are presented as mean values ± SEM from three 
independent experiments. ns not significant or P > 0.05, * P ≤ 0.05, ** P ≤ 0.01, *** P 
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Figure 1. Establishment of EPLM-derived long-term proliferating pro-B cell lines 
from BM and FL. FL and BM-derived CD19-B220+CD117+NK1.1- cells were sorted and 
maintained on OP9 stromal cells plus IL-7 (A) Gating strategy for sorting of CD19+ 
and CD19- B220+CD117+ BM cells. (B) In vitro growth capacity of sorted CD19+ and 
CD19- BM cells on OP9 stromal cells plus IL-7. (C) Comparison of the in vitro growth 
of FL and BM-derived pro-B cells for about 40 days. (D) Representative FACS plots 
showing B220, CD19 and CD117 expression in FL and BM-derived pro-B cells cultured 
for 12 days. (E) RT-PCR analysis of Cd79a, Cd79b, Igll1, Vpreb1, and Actb expression 
in FL and BM-derived pro-B cells cultured for 12 days. (F) Genomic DH-JH 
rearrangement analysis of FL and BM-derived pro-B cells cultures for 12 days.  
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Figure 2. Establishment of EPLM-derived long-term proliferating pro-B cell lines 
from BM and FL under stromal cell free conditions. BM or FL-derived CD19-
B220+CD117+NK1.1- cells were sorted and maintained either on OP9 stromal cells 
plus IL-7 or in the presence of IL-7, SCF and FLT3L without stromal cells. (A) 
Comparison of the growth capacity of BM-derived pro-B cells cultured in the absence 
(black squares) or presence (white circles) of stromal cells for about 40 days. (B) 
Comparison of the growth capacity of FL-derived pro-B cells cultured in the absence 
(black squares) or presence (white circles) of stromal cells for about 40 days. (C) 
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derived pro-B cells cultured for 14 days with or without stromal cells, as indicated. 
(D) Representative FACS plots showing B220, CD19 and CD117 expression on FL- 
derived pro-B cells cultured for 14 days with or without stromal cells, as indicated. 
(E) RT-PCR analysis of Cd79a, Cd78b, Igll1, Vpreb1 and Actb expression in FL and BM-
derived pro-B cells cultured for 14 days in the presence of IL-7, SCF and FLT3L 
without stromal cells. (F) Genomic DH-JH rearrangement analysis of FL and BM-
derived pro-B cells cultured for 14 days in the presence of IL-7, SCF and FLT3L 

























Figure 3. In vivo reconstitution potential of FL-derived pro-B cells propagated in 
vitro. Sub-lethally irradiated CD45.2 B6 Rag2-deficient mice were injected 
intravenously with 107 CD45.1 FL-derived pro-B cells propagated in the presence or 
absence of stromal cells. (A) Representative FACS analysis of B cell populations in the 
spleen and peritoneal cavity (PerC) of WT controls and recipient mice 8 weeks after 
cell transfer of the indicated pro-B cells. (B) Representative picture of a staining for 
IgM (green), IgD (blue), and metallophilic macrophages (MOMA-1 in red) on a spleen 
section of mice reconstituted with FL-derived pro-B cells propagated on OP9 stromal 
cells (20x magnification). In total 28 individual mice were injected: 14 mice with FL-
derived pro-B cells propagated with OP9 stromal cells and 14 mice with FL-derived 


























































































































Figure 4. In vivo reconstitution potential of BM-derived pro-B cells propagated in 
vitro and comparison to the corresponding potential of FL-derived pro-B cells. Sub-
lethally irradiated CD45.2 B6 Rag2-deficient mice (n=21) were injected intravenously 
with 107 CD45.1 BM-derived pro-B cells propagated in the presence (14 mice 
injected) or absence (7 mice injected) of stromal cells. (A) Representative FACS 
analysis of B-cell populations in the spleen and peritoneal cavity (PerC) of WT 
controls and recipient mice 8 weeks after cell transfer of the indicated pro-B cells. 
(B) Absolute numbers of CD19+ IgM+ cells in the spleens of mice injected with BM-
derived pro-B cells and FL-derived pro-B cells (Figure 3). Unpaired student’s t-test. 















































































































































ns: not significant or P > 0.05, **P ≤ 0.01 and ****P ≤ 0.0001. (C) CD19, IgM, and 
CD45.1 expression from a spleen of a CD45.2 B6 Rag2-deficient mouse 8 weeks after 
transfer of 5 x 106 CD45.2 FL-derived pro-B cells and 5 x 106 CD45.1 BM-derived pro-
B cells. Both pro-B cells were propagated stromal cell free. A representative FACS 




Figure 5. T-cell independent responses of mice reconstituted with pro-B cells 
propagated in the absence or presence of stromal cells. B6 Rag2-deficient mice 
were reconstituted with BM or FL derived pro-B cells propagated with or without 
stromal cells and immunized with NIP-Ficoll 8 weeks after cell transfer. Normal B6 
(WT) mice were used as controls and statistical significance compared to WT is 
indicated below the after immunization data points (black squares). Titers were 
defined as the serum dilutions that gave 2 times background OD values in the ELISA 
test. Titers of the indicated antibodies were determined in sera taken 1 week before 
immunization (A and B open symbols) and 2 weeks after immunization (A and B 
closed symbols). (A) IgM anti-NIP titers. (B) IgG anti-NIP titers. (C) Anti-NIP IgG 
subclass titers in the serum of mice reconstituted with FL-derived pro-B cells and WT 
mice. ns: not significant or P > 0.05, * or + P ≤ 0.05, ** or ++ P ≤ 0.01, *** or +++ P ≤ 
0.001, **** P ≤ 0.0001. * represents significance compared to pre-bleed. + 
represents significance compared to titer of WT mice. Each symbol represents an 
individual mouse. Unpaired student’s t test; n = 5-8. Data shown above are mean ± 



































































































































































Figure 6. Anti-NIP responses of WT mice, Rag2-deficient and Rag2cγ double-
deficient mice reconstituted with FL pro-B cells propagated on stromal cells and 
immunized with NIP-Ficoll 8 weeks after cell transfer. Titers were defined as the 
serum dilutions that gave 2 times background OD values in the ELISA test. Titers 
were determined in sera taken 1 week before immunization (A and B open symbols) 
and 2 weeks after immunization (A and B closed symbols) (A) IgM anti-NIP titers. (B) 
IgG anti-NIP titers. (C) IgG1 anti-NIP titers. Sera from B6 mice immunized with NIP-
Ficoll or NIP-OVA were used as positive controls. (D) IgG3 anti-NIP titers. Sera from 
B6 mice immunized with NIP-Ficoll or NIP-OVA were used as positive controls. 
Collective data from two independent experiments are shown and each symbol 
represents an individual mouse. ns: not significant, * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 
0.001, **** P ≤ 0.0001. Unpaired student’s t test; n = 5-8. Data shown above are 




























































































































































Figure 7. In vivo lymphoid reconstitution and immune responses in mice injected 
with in vitro propagated pro-B and pro-T cells. Sublethally irradiated Rag2-deficient 
mice were reconstituted with FL-derived pro-B cells and 4 weeks later with a 3:1 
mixture of in vitro propagated pro-T cells [22] and Foxp3-transduced in vitro 
propagated pro-T cells. Mice were immunized with NIP-OVA 11 weeks after pro-B 
cell transfer and splenocytes analyzed by flow cytometry 3-7 weeks later. (A) IgM 
and IgG anti-NIP responses of reconstituted and immunized B6 Rag2-deficient mice. 
Sera were collected 1 week before and 2 weeks after immunization. (B) 
Representative FACS analysis of splenic B- and T-cell populations 10-14 weeks after 
pro-T cell transfer. (C) Absolute numbers of T and B cells found in the spleens of 
reconstituted mice. ns: not significant or P > 0.05, * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 
0.001, **** P ≤ 0.0001. Unpaired student’s t test; n = 7-9. Numbers above data 
points indicate mean ± SEM. Two independent experiments were performed and 
each symbol represents an individual mouse. 
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